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ABSTRACT 
 
Rifampicin is a major chemotherapeutic agent used against mycobacterial and nocardial 
infections. However, drug resistance in many of these strains has emerged as a one of the 
major challenges being faced by researchers. High level resistance to rifampicin is primarily 
due to mutational alterations in the rpoB gene encoding the β subunit of RNA polymerase. A 
number of cases have been reported in which there is no mutation in this gene leading to the 
discovery of the inactivation methods: decomposition, ADP-ribosylation, glucosylation and 
phosphorylation. Decomposition occurs mostly in Nocardia, Rhodococcus and 
Mycobacterium species. I isolated a new rifampicin resistance gene isolated from the M. 
smegmatis 43756Km1. Its sequence showed that it coded for the enzyme 2-hydroxy-6-
ketonona-2,4-dienedioic acid hydrolase. This enzyme takes part in the hydrolysis of C-C 
bonds of aromatic compounds especially in the metabolic pathway of phenylalanine. 
Rifampicin is bright red but is completely decolourised by iri-mediated decomposition but 2-
hydroxy-6-ketonona-2,4-dienedioic acid hydrolase showed only 75% decolourisation. This 
may be because this enzyme does not completely breakdown the rifampicin molecule.  
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       CHAPTER 1 
                                              INTRODUCTION 
 
1.1 Mycobacteria and nocardioforms 
 
Actinomycetes are a large group of Gram-positive filamentous aerobic or facultative 
anaerobes with G+C rich DNA. Mycobacteria and nocardioforms are part of the 
actinomycetes family. They are ubiquitous in nature and are wide spread in soil and water. 
Mycobacteria as well as the nocardioforms produce characteristic lipids known as mycolic 
acids which are high molecular weight, long chain 3-hydroxyl fatty acids. They also have 
many phenotypic characteristics in common and form a distinct phyletic line. In evolutionary 
terms nocardioforms are also closely related to Mycobacterium. Nocardioforms have been 
assigned to five genera: Corynebacterium, Gordona, Nocardia, Rhodococcus and 
Tsukamurella, based on 16s rRNA (Chun and Goodfellow, 1995). Actinomycetes have 
considerable practical and economical significance as they produce the majority of medically 
useful natural antibiotics. 
 
Mycobacterium smegmatis is a saprophytic species that has been used to explore 
mycobacterial genetics and molecular biology and as a surrogate host to study the virulence 
and the regulatory pathways of Mycobacterium tuberculosis. Because mycobacterial genes 
are poorly expressed from their own promoters in Escherichia coli, M. smegmatis is used as a 
host strain for gene cloning of other mycobacterial pathogenic species. M. smegmatis besides 
sharing more than 2000 homologues with M. tuberculosis, also shares the same unusual cell 
wall structure of M. tuberculosis and other mycobacterial species, making it a perfect 
candidate for such studies (Hopwood, et al., 1988; Snapper et al., 1988, 1990 and Jacobs et 
al., 1989). Other reasons why M. smegmatis is used so much for research as an important 
model for the genetic studies of mycobacterial species is because it rarely causes disease, it 
grows in days instead of weeks and it has a 90% homology to M. tuberculosis. The very slow 
growth rates and pathogenicity issues in working with pathogenic mycobacteria prompted the 
use of M. smegmatis as a model for mycobacterial studies 
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1.1.1 Pathogenicity of mycobacteria and nocardioforms 
 
Most nocardioforms are non-pathogenic and since they are primarily soil inhabitants there are 
widely distributed. Usually nocardioforms are free-living micro-organisms; however, many 
are pathogens of plants, animals and humans. From a medical perspective, mycobacteria 
cause more harm than nocardioforms. The mycobacterial genus comprises of over a 100 
species many of which are pathogenic to humans and animals. This genus contains some 
major human pathogens, such as Mycobacterium tuberculosis, M. leprae and M. ulcerans. 
There are also a number of important opportunistic pathogens within this group, for example 
the Mycobacterium avium-intracellulare complex, commonly referred to as MAC, M. bovis, 
M. kansasii, M. smegmatis and N. asteroids (Table 1). The previously regarded non-
pathogenic strains including Rhodococcus equi, R. erythropolis, R. rhodochrous, Gordona 
bronchialis and Tsukamurella paurometabolum are presently described as opportunistic 
pathogens (Finnerty, 1992). 
 
 
Table 1: Several diseases caused by pathogenic actinomycetes. 
Disease Causative Agent Body sites chiefly 
involved 
Diphtheria Corynebacterium 
diphtheria 
Throat, occasionally 
wounds 
Equine pneumonia Rhodococcus equi Lung 
Leprosy Mycobacterium leprae Skin 
Tuberculosis Mycobacterium  
tuberculosis 
Lung, spine  
 
 
 
Mycobacteria other than the tubercle bacillus sometimes infect humans but they are much 
less virulent in humans than is M. tuberculosis. Infections with these organisms have been 
called nontuberculous mycobacterial infections. Mycobacterium bovis is pathogenic in 
animals and causes a tuberculosis-like disease in cattle whilst M. tuberculosis is mostly 
pathogenic in humans. Mycobacteria can be classified into several major groups for purpose 
of diagnosis and treatment of disease in the case of pathogenic strains:  
 3 
 M. tuberculosis complex, which can cause tuberculosis: M. tuberculosis, M. 
bovis, M. canetti, M. pinnipedii, M. africanum, and M. microtii.  
 Nontuberculous mycobacteria (NTM) are all the other mycobacteria, which 
can cause pulmonary disease resembling tuberculosis, lymphadenitis, skin 
disease, or any other disseminated disease. 
Most exposures and infections by these organisms do not cause disease, infection is usually 
due to a compromised immune system of the hosts; the frail elderly and the HIV- infected are 
highly targeted. M. avium complex (MAC) which is a close relative of M. avium and M. 
intracellulare, accounts for most of these diseases. Other pathogenic species are M. kansasii, 
M. xenopi, M. marinum, M. ulcerans, and the M. fortuitum complex (M. fortuitum, M. 
abscessus, and M. chelonae). 
Mycobacteria are among the most notable human pathogens responsible for much morbidity 
and mortality in Southern Africa as well as elsewhere in the developing world (Lucas et al., 
1994). They are accountable for more fatalities worldwide than any other single pathogen as 
it includes the causative agents of tuberculosis, leprosy and other opportunistic organisms.  
Most mycobacterial infections are difficult to treat since they are capable of withstanding 
adverse conditions such as long periods of exposure to acids, alkalis, detergents, oxidative 
bursts and many antibiotics due to their mycolipid rich cell wall, which is neither truly Gram 
negative nor positive. Furthermore, they are naturally resistant to a number of antibiotics that 
disrupt cell-wall biosynthesis, such as penicillin. Tuberculosis (TB) is the most notable 
disease caused by mycobacteria and statistics for incidence, deaths distribution are discussed 
below. 
 
It is estimated that one third of the world's population, that is, about two billion people are 
infected with TB-causing bacteria (World Health Organization (2009): Fact sheet on 
Tuberculosis) and every 20 sec a person dies from TB. According to the World Health 
Organization (WHO) 98% of TB deaths occur in developing countries and the incidence of 
TB is decreasing or stable in all regions of the world except for Africa. Most of the estimated 
number of cases in 2008 occurred in Asia (55%) and Africa (30%), with small proportions of 
cases in the Eastern Mediterranean Region (7%), the European Region (5%) and the Region 
of the Americas (3%). The five countries that rank first to fifth in terms of total numbers of 
incident cases in 2008 were India (1.6–2.4 million), China (1.0–1.6 million), South Africa 
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(0.38–0.57 million), Nigeria (0.37–0.55 million) and Indonesia (0.34–0.52 million). India and 
China alone account for an estimated 35% of TB cases worldwide (TB WHO 2009 Report). 
Tuberculosis is a chronic, progressive infection which has a period of latency following 
initial infection; therefore some people only get sick possibly years after infection. TB occurs 
most commonly in the lungs but in other active cases, the infection moves from the lungs, 
causing extrapulmonary tuberculosis (Golden and Vikram, 2005). Extrapulmonary infection 
sites include the pleura in tuberculosis pleurisy, the central nervous system in meningitis, the 
lymphatic system and bones and joints in diseases of the spine. Extrapulmonary TB may co-
exist with pulmonary TB as well. TB is also a primary cause of death among people who are 
HIV positive and is responsible for more than 13% of AIDS-related deaths worldwide. HIV 
fuels XDR–TB (Extensively drug-resistant tuberculosis) and once someone is infected with 
TB there is a 5–10% lifetime risk of developing this disease a year.  
 
The TB bacillus develops resistance through incomplete, erratic, or inadequate treatment and 
many TB patients do not complete their full 6-9 month drug regimen (TB Alliance, 2009). 
Treatment of TB is with multiple anti-microbial drugs this is because treatment with any 
single antibiotic always results in survival of a few organisms that have acquired spontaneous 
resistance mutations. Use of multiple drugs makes the occurrence of these simultaneous 
spontaneous mutations to be unlikely.  The most widely used chemotherapeutic agents to 
combat mycobacterial infections are ethambutol, isoniazid, pyrazinamide and rifampicin 
(Grosset, 1989), Table 2.  
 
Cases have been recorded however, whereby a strain resistant to one of the drugs has 
developed and proliferated and also acquired resistance to the other drugs through the same 
process. XDR-TB (extremely drug resistant TB) is a form of TB caused by bacteria that are 
resistant to the most effective anti-TB drugs. It has emerged from the mismanagement of 
multidrug-resistant TB (MDR-TB). Resistance to first line anti-TB drugs (isoniazid and 
rifampicin) defines MDR-TB and XDR-TB is defined as TB that has developed resistance to 
at least rifampicin and isoniazid as well as to any member of the quinolone family and at least 
one of the following second-line anti-TB injectable drugs: amikacin, capreomycin or 
kanamycin (World Health Organisation. 2006). Alternative treatments require a longer 
treatment course with less effective, more toxic, and more expensive second-line drugs. 
Surgery to remove localized areas of lung destruction plays an important role in the treatment 
of advanced cases of MDR-TB or XDR-TB but is not widely available in high-burden 
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regions. 27 countries account for 85% of all MDR-TB cases. The top five countries with the 
largest number of reported cases are India, China, Russian federation, South Africa and 
Bangladesh. XDR-TB has been found in 57 countries to date (WHO: TB Fact sheet, 2009). 
More than 5% or the world’s TB cases may be multidrug-resistant and 10% of those may be 
extensively drug-resistant. Rifampicin is the focus of this study. 
 
 
Table 2: Gene targets for anti-tuberculosis drugs and mutations associated with drug 
resistance (Adapted from Drobniewski and Wilson 1998). 
 
Antimicrobial 
agent 
 
Probable 
targets 
Mutation in genes 
conferring 
resistance 
 
Function of gene 
Rifampicin  RNA synthesis  rpoB DNA-dependent RNA 
polymerase (β subunit) 
Isoniazid  Mycolic acid 
biosynthesis 
katG  
inhA/ mabA 
ahpC 
oxyR 
Catalase/peroxidise 
Fatty acid biosynthesis 
Alkyl hydroperoxide C 
reductase 
Oxidative stress regulator 
Pyrazinamide  Pyrazinamide 
(Pzase) 
pncA Pzase nicotinamidase; loss 
of Pzase gives resistance 
Streptomycin  Protein 
synthesis 
rrs 
rpsL 
16s rRNA 
Ribosomal protein S12 
Ethambutol  Cell wall 
synthesis  
embA, B, C Lipoarabinomannan and 
arabinogalactan synthesis 
Ethionamide  Cell wall 
synthesis 
inhA  Cross-resistance associated 
with inhA mutations 
Ciprofloxacin  DNA synthesis gyrA, gyrB, nor DNA gyrase subunit A and 
B (principally) 
 
 
 
1.2 Antibiotics 
 
Antibiotics are chemotherapeutic substance or compounds that inhibit the growth of micro-
organisms, such as bacteria, fungi, or protozoa. They can be produced by micro-organisms or 
they can be made synthetically in the laboratory. There are a large number of antibiotic 
classes and the major ones are listed in Table 3. Antibiotics are relatively harmless to the 
hosts, they show selective toxicity and therefore can be used to treat infections. 
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Table 3: Antibiotic classes and their modes of action. 
CLASS EXAMPLES TARGET 
Aminoglycosides 
 
streptomycin, kanamycin, spectinomycin translation 
 
Ansamycins rifampicin,  streptovaricin,  Transcription 
Beta-lactams penicillin,  amoxillin cell wall biosynthesis 
Macrolides erythromycin, tylosin Translation 
Tetracyclines oxytetracycline, tetracycline translation 
 
 
 
1.2.1 The ansamycins 
  
This family of antibiotics was first discovered in 1957 and introduced in 1968 (Sensi, 1983) 
as a major addition to the cocktail drug treatment of TB. Most ansamycins (Figure 1) are 
secondary metabolites of actinomycetes which are the producers of most antibiotics. The 
word, ansamycin refers to the group of antibiotics that are characterized by the presence of an 
aliphatic 17-membered ansa bridge connecting two non-adjacent positions of an aromatic 
nucleus. Ansamycins are natural compounds with a macrocyclic structure consisting of an 
aromatic ring system connected to an aliphatic chain that forms an amide linkage to the 
amino group of the aromatic moiety.  
 
Ansamycins are classified into two groups based on the structure of their aromatic moiety. 
The first group has a naphthalene nucleus and is isolated from actinomycetes or higher plants. 
It includes the rifamycin antibiotics, tolpomycin Y, halomicin B, rifampicin and 
streptovaricin A. The second group has a benzene aromatic nucleus and includes the 
macrolide: geldamycin and ansamitocin, ansatrienin, geldamycin, herbimycin and 
mycotrienin. Ansamycins with a naphthalene nucleus are bacteriostatic and inhibit RNA 
polymerase while the benzoquinoid ones affect DNA replication in eukaryotic cells (Lancini 
and Zanichelli, 1977; Lancini, 1983) and are cytotoxic against eukaryotes. Rifamycins are 
used for the treatment of tuberculosis, leprosy, gonorrhoea, and biliary tract and respiratory 
infections. They have been described as having in-vitro activity against Helicobacter pylori. 
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      Figure 1: Structures of representative ansamycins (Adapted from Floss and Yu, 2004). 
 
 
1.2.1.1 The rifamycins 
 
Rifamycins are the naphthalenic ansamycin group of antibiotics and these were originally 
identified in 1957. They are secondary metabolites of the actinomycete Amycolatopsis 
rifamycinica (which was  originally classified as Streptomyces mediterranei, (Margalith and 
Beretta, 1960) reclassified as Nocardia mediterranei, (Thiemann et al., 1969), reclassified 
and reassigned to a newly defined genus as Amycolatopsis mediterranei (Lechevalier et al., 
1986) and most recently reclassified as Amycolatopsis rifamycinica (Bala et al., 2004). 
Despite its transfer to the new genus, Amycolatopsis is closely related to Nocardia species in 
various aspects of its physiological and biochemical nature. A. rifamycinica was found to be 
resistant to rifamycins and this is probably because it has a form of RNA polymerase which is 
not inhibited by rifamycins (Blanco, 1984 et al.,). It has been suggested that there may be a 
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close similarity between the resistance of a producing organism to its own antibiotics and 
such resistance in pathogenic bacteria (Benveniste and Davies, 1973).  
 
The fermentation broth of A. rifamycinica led to the discovery of its derivatives which were 
five biologically-active compounds, designated rifamycin A, B, C, D and E. The only stable 
crystalline compound, rifamycin B, proved to be the least active antibiotic. A vast number of 
chemical modifications to the structures of the rifamycins have been made to obtain 
substances possessing greater activity. As such, the spontaneous expulsion of glycolic acid 
from rifamycin B yielded rifamycin S. Through subsequent reductions this resulted in the 
production of rifamycin SV (Sensi et al., 1960). This compound is very active against Gram-
positive bacteria such as M. tuberculosis and moderately active against several Gram-
negative bacteria. However, rifamycin SV is poorly absorbed in the gastrointestinal tract, so 
oral administration did not give rise to effective levels in the blood stream of patients. 
Therefore, it was modified to create an antibiotic with improved antimicrobial efficacy by 
increasing its activity spectrum and absorption characteristics. A semi-synthetic derivative of 
rifamycin SV called rifampicin was then synthesized. This antibiotic was proven to have 
good oral absorption, and excellent distribution in body tissues and fluids. Furthermore, it had 
a low incidence of adverse reactions to daily administration (Sensi, 1983). 
 
Other semi-synthetic rifamycin derivatives, such as rifabutin (Brogden and Fitton, 1994) and 
rifapentine (Mealy, 1979) were subsequently introduced for clinical use Figure 2. Rifabutin 
in particular is active against a number of rifampicin-resistant clinical pathogens ((Brogden 
and Fitton, 1994) and, is the main drug for treating MAC infection. It is used for patients 
taking drugs (particularly antiretroviral drugs) that have unacceptable interactions with 
rifampicin. Its action is similar to rifampicin, but it has been associated with uveitis when 
used with clarithromycin or fluconazole. Rifapentine on the other hand is used in one dose or 
one week regimens but is not used in children or patients with HIV (because of unacceptable 
treatment failure rates) or extrapulmonary TB. 
 9 
 
Figure 2: Conversion of rifamycin B into rifamycin SV and clinically used derivatives 
(Adapted from Floss and Yu, 2004). 
 
 
1.3 Rifampicin 
 
Rifampicin (Rif) is an odourless red-brown crystalline powder which readily dissolves in 
methanol, dimethyl sulfoxide and chloroform and is slightly soluble in water and acetone. 
Rifampicin (C43H58N4O12) has a molecular weight of 822.94 g\mol. It is an effective broad-
spectrum bacteriostatic drug that is utilised predominantly as part of a cocktail-drug treatment 
of meningitis, AIDS associated mycobacterial infections and tuberculosis. In the treatment of 
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TB it is used in tandem with isoniazid, ethambutol and streptomycin for it to be effective as 
resistance to this antibiotic develops quickly during treatment (Long, 1991). It is also used in 
combination with dapsone and clofazimine in the treatment of leprosy. Rifampicin has many 
significant drug interactions. It accelerates metabolism of anticoagulants, oral contraceptives, 
clarithromycin, corticosteroids, digitoxin, warfarin and many other drugs. The interactions of 
rifamycins and many anti-retroviral drugs is particularly complex; combined use requires 
specialized expertise.  
It is also employed in the treatment of infections caused by Neisseria meningitides (Carter et 
al., 1994), Haemophilus influenzae, methicillin-resitant Staphylococcus aureus (MRSA) 
(Kapusnik et al., 1984), Legionella pneumophila, Streptococcus pneumoniae and other 
pathogens (Abadi et al., 1996). The lipophilic characteristics of rifampicin contribute 
considerably to its absorption and distribution throughout cellular tissues and body fluids. 
Therefore, it is a good candidate to treat the meningitis form of tuberculosis, which requires 
distribution to the central nervous system and penetration through the blood- brain barrier. 
 
The most significant functional groups of rifampicin are the two free hydroxyl (OH) groups 
in positions 21 and 23 of the ansa chain and the presence of a napthoquinone ring carrying 
oxygen atoms at positions C1 and C8 in either the quinine of the hydroquinone form (Fig 3). 
These are the minimum requirements for antimicrobial activity as they are involved in the 
formation of a tight but reversible linkage to DNA-dependent-RNA-polymerase. Any 
modification involving a substitution, the molecular size of which is not important, or 
elimination of the 21- or 23-hydroxyl groups results in an inactive compound (Wehrli and 
Staehelin, 1971). Its most clinically effective derivative has an addition of a 4-methyl-1-
piperazinaminyl group. The emergence of rifampicin-resistant strains has led to the use of 
structural analogues of rifampicin. Rifapentine, rifabutin, and rifalazil are new rifamycin 
derivatives and are tested in rifampicin-resistant isolates.  
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Figure 3: The chemical structure of rifampicin, (Adapted from Campbell et al., 2001) 
 
 
1.3.1 Mode of action 
 
Rifampicin acts directly on messenger RNA (mRNA) synthesis. In 1967, Hartmann et al., 
proposed that the rifamycins might act on RNA synthesis based on the observation that 
rifampicin inhibited uracil uptake in S. aureus. Experiments in E. coli showed that rifampicin 
inhibited transcription by binding to DNA-dependent RNA polymerase and preventing 
elongation of initiated RNA chains beyond a few nucleotides resulting in the accumulation of 
abortive initiation products (Johnston and McClure, 1976). Rifampicin was also shown to 
inhibit M. smegmatis RNA polymerase presumably by a similar mechanism to E. coli (Wiggs 
et al., 1979). Levin and Hatfull in 1993 confirmed that RNA polymerase was the target for 
rifampicin and that the effect of the antibiotic is to inhibit the formation of full-length 
transcripts Fig 4.  
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Figure 4: Mechanisms of RNA polymerase inhibition by rifampicin, (Adapted from 
Campbell et al., 2001).  The RNA itself and the rest of the nucleic acids have not been 
depicted for reasons of clarity. Mg
2+
 is represented by the magenta sphere. The incoming 
nucleotide substrate at the -1 position is shown in green and the -1 and -2 positions that can 
be accommodated in the presence of rifampicin are depicted in yellow.  The RNA further 
upstream (-3 to -8) that cannot be accommodated in the presence of rifampicin is coloured 
pink. The DNA template strand is grey. Rifampicin is shown positioned in its binding site on 
the β subunit. The carbons atoms are coloured in orange while the oxygen in red and 
nitrogen in blue, (Nicholls et al., 1991). The rifampicin is partially transparent, illustrating 
the RNA nucleotides (at -3 to -5) that sterically clash.  
 
Rifampicin inhibits DNA-dependent RNA polymerase (RNAP) in bacterial cells by binding 
its β-subunit, thus preventing transcription to RNA and subsequent translation to proteins. 
RNAP is responsible for the transcription of DNA into RNA, a process achieved by four 
enzymatic steps: DNA binding, chain initiation, chain elongation and chain termination. This 
enzyme consists of five polypeptides: namely, two α subunits, one β subunit, one β′ subunit 
and one σ subunit. The β subunit is an important target for anti-mycobacterial drugs such as 
rifampicin, which exerts its effects by binding to the RNA polymerase and prevents 
transcription by preventing the elongation of initiated RNA chains beyond a few nucleotides, 
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thus inhibiting bacterial growth (Wehrli and Staehelin, 1971; Zillig et al., 1970). The β 
subunit of the DNA-dependent RNA polymerase is encoded by the rpoB gene of bacteria. 
Rifampicin interacts with the β subunit of RNA polymerase when it is in a α2β trimer. This 
halts mRNA transcription, therefore preventing translation of polypeptides. However, it 
cannot stop the elongation of mRNA once binding to the template-strand of DNA has been 
initiated. The rifampicin-RNA polymerase complex is extremely stable and yet experiments 
have shown that this is not due to any form of covalent linkage. It is hypothesized that 
hydrogen bonds and π-π bond interactions between napthoquinone and the aromatic amino 
acids are the major stabilizers, though this requires the oxidation of napthohydroquinone 
which is found most commonly in Rif. It is this last hypothesis that explains the explosion of 
multi-drug-resistant bacteria: mutations in the rpoB gene that replace phenylalanine, 
tryptophan, and tyrosine with non-aromatic amino acids result in poor bonding between Rif 
and the RNA polymerase (Erlich et al., 1973).  
 
 
1.4 Antibiotic resistance mechanisms 
 
Antibiotics like rifampicin are used in the control of infectious diseases. Unfortunately, the 
antibiotics can also select for microbes resistant to these drugs. Resistance to antibiotics has 
been around for as long as the antibiotics themselves, but they have become more serious. 
Some of the mechanisms of resistance are listed below: 
 A reduced ability of the antibiotic to enter into the bacterium due to alterations in the 
structure of the outer membrane, as is the case for a number of mycobacteria (Carter 
et al., 1994). 
 rRNA methylation which prevents inhibition of protein synthesis by the drug. 
 Efflux, (Bambeke, 2000). 
 An increased production of a metabolite that antagonizes the antibiotic. 
 Reduction of cell wall permeability. Abadi et al., (1996) provided evidence that 
changes in cell wall permeability might diminish rifampicin susceptibility. 
 The production of enzymes that inactivate the drug. 
 Alteration of the target site e.g. alteration of PBP-the binding site of penicillin in 
MRSA. 
 Alteration of the metabolic pathway. 
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1.4.1 Rifampicin resistance  
 
There are a number of antibiotic resistance mechanisms as noted from the above discussion 
which occur for the various antibiotics, but in the following section only those which are 
applicable to rifampicin are discussed. 
 
 
1.4.1.1 Rifampicin resistance by reduced cell wall permeability 
 
Resistance to rifampicin, through the prevention of drug influx by modifications affecting the 
permeability of the cell wall has been observed in Neisseria meningitis (Abadi et al., 1996). 
However, in Gram-negative bacteria the cell envelope is effective at restricting permeation by 
antibiotics and the first barrier in the envelope is the outer membrane. The extremely slow 
influx of lipophilic antibiotics is due to the ordering of water molecules within the membrane. 
Experiments done with Tween 80, a substance that alters membrane permeability, revealed 
high-level resistance shown by one strain was due to a decrease in membrane permeability. 
Consequently, the drug was unable to enter the cell. An earlier report also implicated changes 
in cell wall permeability as being responsible for rifampicin resistance in M. avium (Hui et 
al., 1977).  
 
 
1.4.1.2 Rifampicin resistance through active efflux  
 
Efflux pumps are responsible for the removal of toxic substrates, including many classes of 
clinically important antibiotics from within the cell environment. This results in a decreased 
accumulation of the antibiotic within the cell. In 1997, Sánchez et al., identified efflux pumps 
as a contributing factor to Rif resistance by the pathogen Haemophilus influenzae. These 
efflux pumps were actively transporting the drug out of the cell. The study identified a three-
gene complex that was homologous to the acrRAB cluster of E. coli. These genes encode an 
efflux system that is responsible for the extrusion of toxic dyes, detergents (Nikaido, 1996) 
and lipophilic antibiotics (Okusu et al., 1996) from the Gram-negative organism.  
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1.4.1.3 Rifampicin resistance through target-site modifications  
 
Endogenous rifampicin resistance by mutation of the target moiety is ordinarily the most 
widespread. Extensive studies of the development of resistance by M. tuberculosis to Rif 
revealed that in most cases it develops as a result of mutations occurring in a region of the 
rpoB gene, thereby modifying the β-subunit of the RNA polymerase such that it is no longer 
recognizable by the antibiotic. However, the enzyme maintains its binding properties such 
that it can still function normally (Heym and Cole, 1997). Rifampicin resistance in E. coli 
was shown to result mostly from point mutations in four well-defined clusters of rpoB. Some 
strains of M. tuberculosis which are resistant to Rif have shown to possess mutations in the 
largest of these rifampicin resistance clusters. A sequence comparison in the four distinct 
regions of the rpoB gene showed a low level of conservation between prokaryotes and 
eukaryotes. This may be the reason why Rif is not active against eukaryotic RNAPs 
(Campbell et al., 2001).  
 
In M. tuberculosis, mutation in one of 3 loci in rpoB has been associated with Rif resistance. 
Several studies conducted on Rif resistant clinical isolates and multi-drug resistant isolates 
have shown that these mutations are missense mutations, deletions and insertions and occur 
in a 69 base pair (bp) conserved region encoding 23 amino acids (Musser, 1995). Most of 
these mutations are in this Rif resistance-determining region of the rpoB gene coding for 
amino acids 507 through 533. Codons 531, 526, and 516 are reported as the most frequent 
mutation sites, with codon 531 mutations being the most common (Ramaswamy and Musser, 
1998). 
 
In E. coli most mutations are clustered in a 225 bp region of the rpoB gene (Jin and Gross, 
1988). Similar work done in M. leprae (Honore and Cole, 1993) and M. tuberculosis (Telenti 
et al., 1993) identified the same section as the mutational hotspot for Rif resistance. Using the 
E. coli system of codon numbering (Ezekiel and Hutchins, 1968) the codons most prone to 
mutations were found to be 516, 526 and 531.  Rifampicin-resistant bacteria therefore, 
produce RNA polymerases with subtly different β subunit structures which are not readily 
inhibited by the drug. Most Rif
R 
clinical isolates of M. avium, M. intracellulare (Guerrero et 
al., 1994), M. tuberculosis (Ohno et al., 1996) and M. smegmatis (Hetherington et al., 1995) 
do not have mutations in the rpoB gene suggesting other resistance mechanisms are involved 
in response to this challenge by Rif. One of which being the inactivation of the drug. 
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1.4.1.4 Rifampicin resistance by inactivation mechanisms 
 
Analysis of clinical isolates that showed no mutation in the rpoB gene allowed for the 
identification of drug inactivation genes. Inactivation is due the modification of rifampicin by 
enzymatic activity and four mechanisms have been identified and these are decomposition, 
ribosylation, glucosylation and phosphorylation (Table 4). Major changes in the absorption 
spectrum of Rif which are readily visible to the naked eye occur during inactivation. The 
colour of the Rif solution turns from a bright orange to a dull red, as would be expected due 
to the disappearance of the principal absorbance peak in the visible part of the spectrum at 
474nm (Dabbs, 1987).  
 
 
1.4.1.4.1 Ribosylation 
 
This mechanism of inactivation was first identified in 1995 when the inactivated compounds 
were isolated during studies conducted on fast-growing strains of mycobacteria. Ribosylation 
is limited to strains containing MK-9-type menaquinones such as Gordona, Tsukamurella and 
Mycobacterium. Ribosylation of rifampicin has been observed in the fast-growing 
Mycobacterium species: Mycobacterium smegmatis, M. avium, M. parafortuitum, M. vaccae, 
M. flavescens and the closely related slow-growing genera Gordonia and Tsukamurella 
(Dabbs et al, 1995). Further studies showed it is the only resistance mechanism in the closely 
related slow-growing genera Gordona and Tsukamurella. Interestingly, these strains were 
transferred from the genus Rhodococcus only due to differences in their menaquinone (Mk-9 
type) compositions (Stackebrandt et al., 1988).  
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Table 4: Rifampicin inactivation genes of mycobacteria and nocardioforms (Adapted from   
Dabbs, 2004). 
 
Organism (strain) Mechanism Gene Reference 
R. equi 
ATCC 14887 
 
decomposition monooxygenase 
(iri) 
Andersen and 
Dabbs, 1991 
M. smegmatis 
DSM 43756 
ADP-
ribosylation 
(C23) 
 
ADP-ribosyl 
transferase 
(arr) 
Quan et al., 1997 
N. brasiliensis 
IFM 0236 
 
N. otitidiscaviarum 
IFM0239 
 
glucosylation 
(C23) 
 
phosphorylation 
(C21) 
glycosyltransferase 
(rgt) 
 
not known 
Lephoto et al., 
unpublished 
 
A. Rebić, 
unpublished 
 
 
1.4.1.4.2 ADP-ribosylation  
 
 All the processes of ribosylation target the C-23 of the drug. The ADP-ribosylated 
compound is modified by the two-step removal of nicotinamide and ADP resulting in 
ribosylated rifampicin. This mechanism functions in many mycobacterial opportunistic 
pathogens and ADP-ribosylation usually occurs on a nitrogen atom of a protein. Here, the 
ADP-ribose moiety is attached to the C-23 of rifampicin via an O-glycosidic bond (Figure 5) 
and results in 23-O-ADP-ribosyl rifampicin (RIP-TA). The initial ADP-ribosylation step is 
followed by the removal of adenosine monophosphate (AMP) and thereafter 
dephosphorylation gives rise to ribosylated rifampicin, (Imai et al., 2000).  
 
Several ADP-ribosylation reactions have been described in both eukaryotes and prokaryotes. 
It is highly unlikely that it is present to combat rifamycins as it is more active against semi-
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synthetics than the natural antibiotic (Gianniosis, 2006). More experimentation needs to be 
performed to elucidate the function of this protein within the cell.  
                   
 
Figure 5: Chemical structure of ADP-ribosylated rifampicin (Adapted from Imai et al., 
1999). The adenosine diphosphate (ADP) group is shown in blue and the ribose sugar in red. 
Ribosylated rifampicin is achieved through two steps: the first involves the removal of 
adenosine monophosphate (AMP) and the second is dephosphorylation.  
 
 
1.4.1.4.3 Glucosylation 
 
Glucosylation is any process by which a glucose sugar moiety is added to another molecule.  
Glycosyl transferases are the enzymes responsible for catalyzing the transfer of sugar 
moieties from one compound to another. Glucosylation involves the replacement of the free 
hydroxyl group at position 23 of the ansa link with D-glucose by a glucosyl-transferase 
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enzyme (Yazawa et al., 1993) thereby, rendering the drug inactive. Detailed studies of 
Nocardia spp. revealed that many Nocardia spp. were inherently resistant to rifampicin and 
this was reported to be as a result of an inactivation enzyme mechanism that was present in 
these bacteria (Yazawa et al., 1993; Dabbs et al., 1995). Glucosyl-transferases play a crucial 
role in a self-defence mechanism by organisms that produce this antibiotic. The 
chromatographic analysis of the inactive forms of Rif in N. brasiliensis revealed two 
compounds, RIP-1 and RIP-2. These compounds were identified using NMR Spectroscopy to 
be 3-formyl-23-(O-(β-D-glucopyranosyl)) rifamycin SV and 23-(O-(β-D-glucopyranosyl)) 
rifamycin respectively, the glucosylation products of Rif. The gene encoding the 
glucosylation, rgt, was cloned and characterized from the opportunistic pathogen Nocardia 
brasiliensis. Yazawa et al., (1993) showed that 39/40 strains of N. brasiliensis they tested 
exhibited a minimum inhibitory concentration of >100F g/ml with Rif. Based on this they 
concluded that N. brasiliensis along with N. otitidiscaviarum are naturally resistant to Rif, 
which could be explained by glucosylation. However, from the family of the rifamycins, it 
was discovered that streptolydigin and streptovaricin are not inactivated by glucosylation and 
rifamycin SV is inactivated more slowly.  
 
 
1.4.1.4.4 Phosphorylation 
 
Phosphorylation results in the substitution of the free hydroxyl group at position 21 of the 
ansa link with a phosphate. This mechanism is dominant in the genera Nocardia and 
Rhodococcus (Yazawa et al., 1994). Nocardia otitidiscaviarum as well as R. rhodochrous 
have been found to have the ability to inactivate rifampicin by phosphorylating the 21-OH 
group (Yazawa et al, 1993). 
 
 
1.4.1.4.5 Decomposition 
 
Decomposition is the most widespread of the four inactivation mechanisms and it has been 
detected in Nocardia, Rhodococcus and Mycobacterium, (Tanaka et al., 1996). 
Decomposition was observed in N. farcinica and N. nova. In Rhodococcus, decomposition 
was observed in R. erythropolis and R. globerulus. Decomposition of rifampicin is believed 
to result from the transfer of a single oxygen atom to the naphthalenyl moiety of the drug 
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causing it to break apart (Anderson, 1996). The inactivation process results in the antibiotic 
being decolourized from its red-brown colour. This mechanism was discovered to be species-
specific among mycolic acid-containing bacteria. The Rif decomposition gene was cloned 
from R. equi and showed high sequence similarity to the genes encoding the monooxygenases 
(hydroxylases), which act on phenolic compounds and may be involved in the biosynthesis of 
polyketides (Andersen et al., 1996). The gene responsible for this Rif resistance was called 
the iri (inactivation of rifampicin). This mechanism may also be present in other related 
streptomycetes such as Arthrobacter oxydans C1S and M. smegmatis DSM 43756. A survey 
of other organisms found no other groups were able to inactivate rifamycins, with the 
exception of Bacillus. 
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CHAPTER 2  
                     JUSTIFICATION 
Antibiotic resistance is on the rise globally and it is mainly driven by selective pressure 
imposed by inappropriate antibiotic use. In the case of tuberculosis which is caused by 
Mycobacterium tuberculosis, antibiotic resistance is due mainly to inappropriate usage of the 
prescribed drugs of treatment as well as to alterations of the prescribed drugs. Tuberculosis 
remains a global health problem of enormous proportions, as it is attributed to a 7% loss in 
the GDP of some countries (World Health Organization (2009): Fact sheet on Tuberculosis). 
This vastly affects the economies of most developing countries as it is most prevalent there. It 
has been estimated that there are 1 billion (20% of the world’s human population) people 
infected worldwide, with 10 million new cases and over 3 million deaths per year. 
  
Today's TB drug regimen takes too long to administer and requires too many pills. The 
current treatment courses, consists of four medicines: isoniazid, ethambutol, pyrazinamide 
and rifampicin. This regimen works for active, drug-susceptible TB, as long as patients 
complete the six- to nine-month treatment. If the treatment is not completed drug-resistant 
strains develop that take up to two years or more to treat with second-line drugs, which often 
cause severe side effects. In addition to this, it has been discovered that there has been an 
emergence of MDR and XDR strains of M. tuberculosis which are untreatable with any 
existing antibiotics (TB Alliance, 2009). 
 
It has been over 40 years since a new TB drug has been developed, rifampicin which was first 
discovered in 1963 remains one of the important frontline antibiotics necessary for treating 
tuberculosis and leprosy. However, cases of the strain becoming resistant to it have been on 
the increase and it is therefore important that there is a detailed understanding of the 
mechanism(s) involved in conferring rifampicin resistance in this genus that will assist in the 
improvement of antimicrobials used in the treatment of infections caused by these organisms.  
 
2.1 Aim of this work 
 
My research followed the work of Susan Andersen (1996) on the inactivation of rifampicin in 
Rhodococcus equi. She identified a monooxygenase-like gene sequence in this bacterium 
 22 
whose product confers increased resistance to rifampicin. The monooxygenase-like enzyme 
leads to the decomposition of rifampicin resulting in complete decolourisation of the 
antibiotic (Dabbs, 1987). The antibiotic is disrupted to a degree such that no information on 
the nature of the enzymatic attack could be obtained (Yazawa et al., 1993). Therefore, my 
work was to: clone and characterise the corresponding gene from mycobacterial strain M. 
smegmatis 43756Km1, the parental M. smegmatis DSM 43756 believed to inactivate Rif 
through both ribosylation and decomposition.  
 
 2.2 Specific experimental objectives 
 
• To make RifR mutants of M. smegmatis 43756Km1 (arr gene is disrupted) and to confirm 
whether they inactivate rifampicin by decomposition.  
• To construct one or more genomic libraries of M. smegmatis 43756Km1. 
• To clone the iri-like gene of M. smegmatis 43756Km1. 
• To construct a restriction map and use this to subclone and identify the minimum necessary 
DNA. 
• To sequence the gene. 
• To characterize these mutants in terms of altered antibiotic MIC and altered kinetics of 
inactivation. 
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CHAPTER 3 
            MATERIALS AND METHODS 
 
3.1 Bacterial Strains 
 
Bacterial strains used in this work are listed in Table 5 plasmids in Table 6  
 
Table 5: Bacterial strains used in this work. 
Strain Relevant characteristics Source 
Escherichia coli 
MM294-4 endA1, hsdR17, gyrA E. Dabbs 
λMM294-4 λ lysogen of MM294-4 E. Dabbs 
Bacillus subtilis 
1A3-1 Spc
R 
rifampicin assay organism E. Dabbs 
Rhodococcus 
      Equi Type strain E. Dabbs 
erythropolis 4277 Type strain E. Dabbs 
erythropolis SQ1 Highly transformable S. Quan and E. Dabbs 
erythropolis 1069 Type strain DSM 
rhodochrous Ri8  iri
- 
S. Quan 
rhodochrous 01 Type strain E. Dabbs 
opacus HP-LA1 Type strain E. Dabbs 
Mycobacterium   
smegmatis DSM 
43756 
Type strain DSM 
smegmatis 43756Km1 arr disrupted by a kanamycin cassette  S. Quan 
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3.2 Media and Growth Conditions   
 
Luria-Bertani (LB) (Appendix A) media was used for growing E. coli and Bacillus strains 
and Brain-heart infusion (BHI) media was used to grow all mycobacterial and rhodococcal 
strains. Liquid cultures were obtained by inoculating single bacterial colonies into 5 ml LB 
medium and incubating at 37°C overnight. For short-term storage, E. coli strains were kept 
on LB-agar plates (Appendix A) at 4°C. Bacillus strains were kept on LB-agar plates at room 
temperature until they sporulated for long-term storage.  
 
Table 6: Plasmids and phages used in this work. 
Plasmid/ 
Phages 
Relevant characteristics Source  
pDA71 E. coli-Rhodococcus shuttle vector  S. Quan and E. Dabbs  
pDA71* E. coli-Rhodococcus shuttle vector with Eco RI 
suicide gene inactivated 
E. Dabbs 
pUC 18/19 sequencing vector with multiple cloning sites Fermentas 
pGEM-T-Easy E. coli high copy number vector, lacZ′ gene, 
single 3′ thymidine overhangs, SP6 and T7 
promoters 
 
Promega 
pNV18 E. coli and M. smegmatis shuttle vector Promega 
pNV19 E. coli and M. smegmatis shuttle vector Promega 
K04 R. erythropolis SQ1 phage Y. Shibayama 
W12 R. erythropolis SQ1 phage Y. Shibayama 
 
 
 
3.2.1 Generation of spontaneous mutants 
 
 Bacteria were grown to stationary phase and 100 µl of this bacterial culture was spread on 
LA plates containing a high concentration of the appropriate antibiotic. These were incubated 
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for 3 or more days, the resulting colonies were streaked onto the appropriate antibiotic 
containing plates.     
 
 
 3.3 Spot testing and the determination of minimal inhibitory concentration (MIC)  
 
The minimal inhibitory concentration (MIC) of antibiotics was determined on LB-agar plates 
for E. coli strains by the agar dilution method. Freshly grown colonies were inoculated into 
200 µl of sdH2O per well. This was replica plated onto LB-agar plates containing the 
dilutions of antibiotics starting from the highest concentration. Prior to use, the replicator was 
sterilized by flaming.  E. coli spot tests were analysed after incubation at 37°C for 24 hrs. The 
antibiotic concentration at which there was no confluent growth was taken as the MIC. These 
tests were done in triplicates, the average result was used in drawing graphs and the standard 
deviation of the three results was used to incorporate error bars within these graphs.  
  
    
3.4 Inactivation assays 
 
The ability of different strains and plasmid containing mutants to inactivate Rif and related 
antibiotics was assayed using the plate assay method. 
 
A pre-culture of each test organism was grown in 5 ml of BHI and grown at 37°C on the 
wheel overnight. An aliquot of 50 µl of each strain was inoculated into 5 ml of fresh BHI and 
grown for 3 hours at 37°C. After which, 20 µg/ml of Rif was added and left to grow 
overnight at 37°C. A control was made by adding 20 µg/ml of Rif to 5 ml of BHI and this 
was left on the wheel overnight as well. No cells were added to the control. The assay 
organism, B. subtilis 1-A3 was also grown at 37°C in 5 ml of LB broth. The time when the 
antibiotic was added was taken as zero and assays carried out at various times after that (24, 
48, 72 hrs).  100 µl of B. subtilis was diluted in sterile distilled water (1:10) and then spread 
on ½ LA streptomycin (200 µg/ml) plates. ½ LA plates contain half of the normal agar 
usually added to make LA plates. The lower concentration of agar allows for easier diffusion 
of Rif. 
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Wells where made in agar using the blunt end of a Pasteur pipette. The wells were then filled 
with 70 µl of the cultures being tested, care being taken not to spill any on the sides. The 
plates where then incubated at 4°C for 4 hrs, to allow the rifampicin to diffuse in the media. 
Subsequently, they were incubated at 37°C until zones of inhibition became visible. 
 
 
3.5 Phage plaquing test 
  
2 ml of LB was added into a test tube, to this 3 ml of sloppy agar (½ LA) and 20 µl of Hs7-1 
was introduced, this was mixed by rolling gently between the hands. This mixture was then 
poured onto CaCl2 and MgCl2 plates and allowed to set in a 30ºC incubator for 15 min. The 
Ca
2+ 
and M
2+
 ions are responsible for stabilising the phages such that the phage is effectively 
adsorbed onto the host cell (Hs7-1) surface. K04 and W12 phages were then spotted onto 
these plates, allowed to dry and incubated at 28ºC overnight. 
 
 
3.6 DNA preparations  
 
3.6.1 E. coli bulk plasmid DNA preparation  
 
The plasmid being extracted was pDA71 which is a cloning vector. It is 8.8kb and has 
selectable markers (Amp
R 
in E. coli and Cam
R 
in Rhodococcus) and it has a multiple cloning 
site in EcoR, an endonuclease gene, which make it a suitable cloning vector. Plasmid pDA71 
allows selection of transformants with inserts because of this “suicide” gene. 
 
A culture of E. coli carrying pDA71 was grown in 100 ml of LB supplemented with 100 
µg/ml of Amp. The culture was grown with gentle agitation at 37°C overnight. Cells were 
harvested by centrifugation in a Beckman JA-10 rotor at 6 000 rpm for 10 min and then re-
suspended in 5 ml of solution I. 10 ml of solution II was then added to the cell suspension, 
mixed gently by inversion and left to stand at room temperature for 30 min. This allows for 
lysis of cells. Afterwards, 7.5 ml of chilled solution III was added and the tube was shaken 
vigorously and then left in ice-water slurry for 15 min. This was centrifuged in a pre-chilled 
JA-20 rotor at 15 000 rpm for 10 min. 
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The supernatant was decanted into a clean Beckman centrifuge tube and warmed at 37°C for 
2 min. 12 ml of isopropanol was added and left to stand at room temperature for 5 min on the 
bench. The DNA was then precipitated by centrifuging in a warm JA-20 rotor at 15 000 rpm 
for 10 min. The resultant DNA pellet was washed with 2 ml of ethanol (96%) and re-
centrifuged for 3-5 min at 15 000 rpm at room temperature, excess liquid was blotted on a 
paper towel. The DNA pellet was vacuum-dried for 20 min and then re-suspended in 4 ml TE 
buffer for 2 hrs at 30°C in a shaking water bath. TE buffer contains EDTA which chelates 
Mg
2+
 ions in the DNA solution hence protecting DNA from degradation by nucleases. 
 
 4.3 g of CsCl was added and dissolved by gently shaking. Thereafter, 400 µl of a 1% EtBr 
solution was added and the refractive index adjusted to between 1.387 and 1.389 (0.001 units 
= 100 mg CsCl if the index was below or 0.001 units = 100 µl TE if the index was over). The 
mixture was loaded into a Beckman Quick-seal tube using a Pasteur pipette. The tube was 
sealed, balanced and ultra-centrifuged overnight at 40 000 rpm in a Beckman vertical VTi 
65.2 rotor for 22 hrs.   
 
The tube with the DNA was then viewed under UV and the lower layer which is the plasmid 
DNA was extracted. EtBr was removed from the DNA by extracting three times with 200µl 
of butanol. Before the DNA can be used a salt-ethanol precipitation was performed. 
 
 
 
3.6.2 Mycobacterial bulk genomic DNA preparation 
 
The complex structure and low permeability of the cell wall of mycobacterial cells make 
them difficult to lyse and extract DNA. The cell walls are thick and contain large amounts of 
lipids, among which are mycolic acids which are resistant to simple lysis processes with 
strong alkali and acids. Therefore, commonly employed methods of isolating DNA yield 
either low quantity (due to incomplete lysis of bacterial cell wall) or poor quality DNA 
resulting in low sensitivity of the test. Successful extraction of mycobacterial DNA had to 
include the following steps as a result: 
1) Harsh physical treatment to weaken the mycobacterial cell wall (i.e. freezing at 
20°C or boiling bacterial suspension for 10 min). 
2) Chemical treatment to lyse the mycobacterial cell wall. 
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3) DNA purification steps including treatment with proteinase K to remove proteins. 
 
A culture of Mycobacterium smegmatis 43756Km1 was grown to stationary phase for about 2 
days in 200 ml of BHI (0.5% glycine and 0.5 % Tween 80) on a shaker at 37°C. 
Mycobacterial cells tend to clump when growing in liquid media therefore, to reduce this 
clumping add 0.05% Tween 80 and/or (3-5) glass beads were added to the BHI, and the 
glycine weakens the cell wall. The BHI was supplemented with 200 µg/ml of Kan.  
 
Cells were precipitated by centrifugation in a Beckman JA-10 rotor at 6 000 rpm for 10 min 
at room temperature. The cells were resuspended in 5 ml of TE and boiled for 10 min at 
100°C. This was necessary for weakening the linkages between the lipid contents of 
mycobacterial cell wall, resulting in release of chromosomal DNA in solution. This was 
allowed to cool for 2-5 min and 5 mg/ml lysozyme was added and transferred to a fresh 
Sorval tube, which was incubated for 45 min at 37°C on a shaker. The cells were then 
centrifuged at 8 000 rpm for 5 min in a Beckman JA-20 rotor and resuspended in 4 ml of TE. 
400 µl of solution B (TE + 15% SDS) was added to the cells to which a minute quantity of 
proteinase K was added. The proteinase K is responsible for inactivating nucleases which 
might otherwise degrade the DNA during purification. The tube was then incubated at 45°C 
for 30 min. 
 
The viscous solution was transferred to a 50Ti tube and spun at 40 000 rpm for 30 min in a 
Beckman L55 ultracentrifuge. The supernatant was transferred to a clean centrifuge tube, 
4.4g of CsCl was added, and the tube was inverted several times to mix. The solution was 
centrifuged at 15 000 rpm for 15 min and the liquid was decanted. 400 µl of (1%) EtBr 
solution was added and the refractive index adjusted to between 1.391 and 1.392.  
 
The solution was loaded into a Beckman Quick seal tube and centrifuged for 22 hrs at 40 000 
rpm in a VTi65.2 rotor in a Beckman L7-55 ultracentrifuge. The genomic DNA was extracted 
from the tube using a needle attached to a hypodermic syringe, the EtBr was removed by 
butanol extraction and the genomic DNA was precipitated with ethanol. 
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3.6.3 E. coli mini plasmid preparation  
 
Individual bacterial colonies were inoculated into 1 ml of LB containing 100 µg/ml of Amp. 
This was incubated at 37°C on a shaker for at least 5 hrs or overnight. The culture was 
transferred to a sterile Eppendorf tube and the cells were harvested by microfuging for 1 min 
at room temperature. The supernatant was decanted off and the cell pellet re-suspended in 80 
µl of solution I by vortexing. Then, 160 µl of solution II was added, mixed gently by 
inversion and left to stand on the bench for 15 min. Thereafter, 120 µl of solution III was 
added. The mixture was shaken vigorously and placed on ice for 5 min. Cellular debris was 
removed by microfuging at 4°C for 10 min. The supernatant was transferred to a clean sterile 
Eppendorf tube and warmed in a 42°C water bath for 2 min.  
 
220 µl isopropanol was added and left to precipitate 5 min at room temperature. Isopropanol 
selectively precipitates DNA leaving RNA and polysaccharides in solution. This was 
followed by centrifugation for a further 5 min. The pellet was washed with 150 µl of 96% 
ethanol and dried in a speed vacuum for 20 min. The DNA was then re-suspended in 150 µl 
of sdH2O with 10 mg/ml ribonuclease which digests any remaining RNA contamination. 13.5 
µl was then analysed on an agarose gel.  
 
 
3.6.4 Rhodococcus plasmid DNA mini-preparation 
 
Cultures were inoculated in 300 µl of LBSG (LB + 3% glycine and 10% sucrose) 
supplemented with 40 µg/ml Cam and grown for 2-3 days at room temperature on the wheel. 
200 µl of the cells were transferred to a sterile Eppendorf tube and the cells where harvested 
by microfuging for a minute. The pellet was resuspended in 200 µl of TE containing 5 mg/ml 
lysozyme. The suspension was then incubated in a 37°C water bath for an hour. After 
incubation 40 µl of TE-SDS (10%) was added to the suspension, mixed by inverting and left 
at room temperature for 10 min. 40 µl of 5.0M potassium acetate (pH 6.0) was added and the 
mixture was shaken vigorously. This was followed by incubation on ice for 5 min and 
microfuging at 4°C for a further 5 min. The supernatant was then transferred to a tube and 
further purified with a phenol-chloroform extraction. The DNA was ethanol precipitated and 
dried under vacuum for 20 min. The pellet was re-suspended in 50 µl of sdH2O water. 
 
 30 
3.7 DNA manipulations  
 
3.7.1 DNA precipitation 
 
3.7.1.1 Salt and ethanol precipitation  
 
DNA was precipitated using a 0.1 volume of 1M NaCl and 2 volumes of 96% ethanol. The 
mixture was microfuged at 4°C for 20 min. The supernatant was decanted and the remaining 
liquid removed by blotting on a paper towel. The DNA pellet was vacuum-dried for 20 min 
and re-suspended in 100 µl of sdH2O. Contamination with RNA was removed by incubating 
the plasmid DNA solution containing freshly boiled RNAse (10 mg/ml) for 15 min at 65°C.  
 
 
3.7.1.2 Ethanol precipitation 
 
CsCl is removed from a DNA solution by ethanol precipitation. The salt was removed by 
adding 200 µl of sdH2O and 700 µl of 96% ethanol to 100 µl of DNA; this was left on ice for 
10 min and precipitated by centrifugation for 20 min at 4°C. The DNA pellet was dried under 
vacuum for 20 min and re-suspended in 100 µl of sdH2O. 
 
 
3.7.2 DNA preparation from CsCl density gradients  
 
Ethidium bromide (EtBr) was removed from the DNA by thorough mixing with a 0.1 volume 
of butanol. The procedure had to be repeated at least 3 times before all traces of EtBr were 
removed. This left the DNA in a CsCl solution. The DNA was stored at -20°C until required. 
It then undergoes ethanol precipitation before being used. 
 
 
3.7.3 Phenol-chloroform extraction 
 
DNA was extracted from aqueous solution by phenol and chloroform. Phenol removes 
restriction enzymes and other proteins including agarose. Chloroform facilitates the 
separation of aqueous and organic phases as well as removing phenol. Both phenol and 
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chloroform denature the proteins which can be removed easily as proteins partition into the 
organic phase, leaving the DNA behind in the aqueous phase.  
 
50 µl of TE-saturated phenol (Appendix B) was added to 100 µl of DNA, mixed by inversion 
and microfuged at room temperature for 5 min to separate the organic and aqueous phases. 
The upper aqueous layer was then transferred to a sterile Eppendorf tube and where 
necessary, as in the case of extracting DNA from low gelling agarose, a further phenol step 
was performed until there was no visible protein at the interface. Then, a 100-120 µl of 
chloroform was added to the aqueous layer and mixed thoroughly by inversion. The organic 
and aqueous layers were separated by microfuging for 3-5 min at room temperature. The 
upper aqueous layer was removed to a fresh Eppendorf tube and the DNA precipitated with a 
0.1 volume of NaCl as outlined above in section 3.6.1.1.  
 
 
3.7.4 Restriction enzyme digestion   
 
Enzymes were obtained from Boehringer Mannheim or Fermentas and used according to the 
manufacturer’s instructions. The total volume of a digestion reaction was 15 µl (13.5 µl DNA 
and 1.5 µl 10x buffer). The mixture was tapped briefly to ensure even buffer distribution and 
spun down for a few seconds. 0.5 µl of restriction enzyme was added and the contents mixed 
and briefly re-spun. Digestions were incubated at the appropriate temperature for maximal 
enzyme activity for at least 4 hrs. For double digestions an appropriate buffer in which both 
enzymes showed suitable activity was selected, otherwise the digestions were performed 
sequentially starting with the enzyme that required the lower pH buffer. Where the procedure 
had been for determining fragment sizes or existence of enzyme sites these digestions were 
loaded onto agarose gels. Where the process had been carried out for subsequent ligation the 
enzyme was removed by the phenol-chloroform method.  
 
 
3.7.5 Ligation of DNA 
 
DNA ligases catalyze the formation of phosphodiester bonds by joining 3′-hydroxyl and 5′-
phosphate ends of double stranded DNA. T4 DNA ligase (Fermentas) was used because it 
ligates not only sticky ends, but also blunt ends of DNA. The total volume for ligation was 
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kept minimal at 20 µl. Ligation buffer and the appropriate volume of sdH2O were added to 
the DNA sample, mixed by tapping and microfuged for 5 sec. Subsequently, 1 µl of ligase 
was added, this was further remixed and re-spun. Ligation was performed in a water bath at 
22°C for roughly 12 hrs. This DNA was then used in transformations. 
 
 
3.7.6 Agarose gel electrophoresis 
 
Agarose was prepared in 0.5x TBE at concentrations of 0.4; 0.8; and 1.2%. Gels were 
prepared by adding 2.5 µl of 1% EtBr to 25 ml of agarose. These were run in 0.5 TBE at 
100V at room temperature. 0.4% gels were used for genomic DNA and the 0.8% gels for 
small DNA i.e. vector inserts, restriction fragments and plasmid DNA.  
 
 
3.7.6.1 Freeze/ squeeze DNA extraction 
 
This method was used to separate and extract DNA from the agarose gel after 
electrophoresis. Digested DNA was run on agarose gel and viewed under a UV illuminator 
and the DNA inserts excised using a scalpel into Eppendorf tubes. The samples were then 
incubated at -70ºC for 30 min to 2 hrs and then thawed at room temperature. Once thawed the 
resultant supernatant was collected into a fresh Eppendorf.  The remaining agarose was 
crushed and microfuged and supernatant collected into the above Eppendorf. The thawing, 
crushing and microfuging was repeated once more and the resultant supernatant was collected 
and phenol-chloroformed to purify the DNA.  
 
 
3.7.6.2 Low gelling agarose electrophoresis 
 
Low molecular weight agarose gel electrophoresis was used to isolate DNA fragments from a 
0.8% gel.  Running buffer was allowed to chill at 4ºC for about 2 hrs before use. A gel was 
made with 8 wells and 35 µl of the Pst I digested DNA was added to each well. 
Electrophoresis was conducted at 95V and 23 mA for 2½-4 hrs at 4ºC or until the second 
band reaches the end of the gel. The gel was viewed under a UV illuminator for the shortest 
time possible and inserts were excised using a scalpel into Eppendorf tubes. This was melted 
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at 62ºC for 20-30 min. The DNA-melted agarose underwent 3 phenol extractions followed by 
a single chloroform extraction before the DNA was salt and ethanol precipitated to purify it. 
The DNA was resuspended in the lowest quantity (20-30 µl) of sdH2O.  
 
 
3.8 DNA calibration 
 
This exercise is necessary to determine the optimal amounts of plasmid and genomic DNA 
that produce ligations that yield the maximum number of transformants during construction 
of a genomic library. 
 
 
3.8.1 Vector calibration 
 
Different (2-8 µl) volumes of the digested plasmid were religated back using T4 DNA ligase.  
These were then transformed into E. coli MM294-4 using the CaCl2 method of 
transformation, spread on LA plates supplemented with 100 µg/ml of Amp and the plates 
were incubated overnight at 37ºC. A no DNA (0 µl) control was used as the negative control 
and the positive control was pDA71*. The volume that produces the least transformants, 0-5 
are an acceptable range, was then used to make the genomic library. This procedure is done 
to ensure that during the genomic library construction the plasmid DNA being transformed 
carries the clone to be transformed considering that if pDA71 re-ligates back onto itself the 
suicide Eco-R gene is functional therefore cells with this DNA will not grow on the Amp 
plates. 
 
 
3.8.2 Genomic DNA calibration 
 
The volume of genomic DNA to be used with the volume of plasmid determined in 3.8.1 was 
also determined by first treating the genomic DNA with a fixed volume of plasmid DNA and 
different volumes of genomic DNA and setting up the ligations. The ligations were then 
transformed into E. coli MM294-4. A negative control (no DNA) and a positive control 
(pDA71) were set up as well. The volume that gave the highest transformants per plate was 
then chosen to be used in the construction of the genomic library. 
 34 
3.8.3 Transformations and calculation of the number of transformants needed to 
complete the genomic library 
 
Number of clones = In (1-P)    
          In (1-a/b)      where  N = number of clones 
           P = probability of having the clone in the library 
           a = average insert size 
           b = genomic DNA size 
 
 
 
3.9 Transformations 
 
3.9.1 Escherichia coli CaCl2 mediated transformations 
 
A single colony of E. coli MM294-4 was inoculated into 5 ml of LB with 10-15 µl of 10 
mg\ml Nal grown overnight on the wheel at 37°C. 200 µl of the pre-culture and 0.5% glucose 
was added to 20 ml of LB, and incubated for 1 hour and 45 minutes at 37°C. This was grown 
with vigorous aeration. The transformation buffer and the centrifuge tubes to be used were 
placed in an ice box at this stage and all subsequent procedures required all equipment and 
reagents to be ice cold when used. The centrifuge and rotor were cooled 15 min before use 
and kept cool for the next steps as well. After the incubation period cells were placed in an 
ice-water slurry for 5 min and centrifuged at 10 000 rpm for 5 min. The supernatant was 
decanted and discarded after centrifuging. The cell pellet was re-suspended in 10 ml 
transformation buffer and left in ice for 15 min or more. 
 
This was centrifuged for 5 min at 10 000 rpm after the incubation period. The supernatant 
was discarded and re-suspended gently in one fifth volume transformation buffer and left on 
ice for 2-24 hrs. The DNA (ligations) to be transformed were placed on ice at least 10 min 
before being added to 100 µl of the competent cells. These were aerated gently and briefly by 
passing air through them. The cells were then left on ice for 10 min to allow diffusion and 
where then heat shocked at 44°C for 90 seconds. 
 35 
0.5 ml of warm LB was added and incubated for an hour at 37°C with the Eppendorf caps 
open. This allows for phenotypic expression of antibiotic resistance. The cells were then 
spread on Amp 100 µg/ml plates and dried at 37°C for 24 hours with the plate lids upward. 
 
 
3.9.2 Rhodococcus PEG-mediated transformations 
 
The recipient strain R. rhodochrous Hs7 was inoculated into 5 ml of 3% glycine LBSG and 
grown for 2-3 days at 30°C on the wheel. After the culture reaches mid-log growth phase, 
cells were harvested from 1.2 ml of culture by microfuging for a minute, washed with basal 
buffer (B buffer) and microfuged for 30 seconds.  The B buffer was decanted and the cells 
were resuspended in 1 ml B buffer containing 5 mg/ml lysozyme, freshly added. The tube 
was incubated for an hour in a 37°C water bath with inversion every 10 min. 
 
Roughly 40 min into the above incubation period the PEG was sterilized under UV light for 
10 min. During this time the protoplast buffer (P buffer) was made (Appendix B). This was 
used to make the P-PEG buffer, which was prepared by adding 1 ml of the P buffer to 0.5 g 
of PEG. After incubation the resultant protoplast suspension was microfuged for 15 seconds, 
washed with 1 ml B buffer and resuspended in 500 µl P buffer.   Aliquots (100 µl) of the 
protoplast suspension were transferred to Eppendorf tubes and plasmid DNA, (10 µl) was 
added to each tube. The tube contents were mixed by gently bubbling air through the 
solution. The tubes were incubated for 10 min at room temperature and an equal volume of P-
PEG was added to each tube while bubbling air through the contents so as to mix the two 
phases.  
 
The content of the tubes were spotted on chilled regeneration media and spread using a 1 ml 
pipette. These were incubated for 10 hrs at 28°C, to allow phenotypic expression of the 
antibiotic resistance gene. 500 µl of 2 mg/ml Cam stock solution was used as an underlay. 
The plates were incubated for 3-5 days at 28°C. 
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4.0 Sequencing 
 
The vector used for sequencing was pUC18.  3 µl of the vector was resuspended in 100 µl of 
sdH2O, digested with Pst I and incubated at 37ºC overnight. So as to prevent the vector from 
religating back onto itself phosphatase was added to the reaction mixture. Addition of the 
dephosphorylation buffer was not necessary since phosphatase functions equally well in the 
digestion buffer. The reaction mixture was incubated further for 5 hrs or more at 37ºC. After 
incubation the enzyme was removed by phenol-chloroform and the DNA extracted was 
resuspended in triple the original volume of sdH2O. 
 
The DNA insert (from the clone) isolated by low gelling agarose electrophoresis was then 
ligated into pUC18. Ligations of the insert and plasmid were set up using 2 µl of digested 
pUC18, 15 µl of insert, 2 µl ligation buffer and 1µl of T4 DNA ligase and incubated at 22ºC 
for 2 hrs. This was transformed into E. coli MM294-4 using the CaCl2 method. Control 
ligations included vector only (positive), no vector (negative) and insert only (negative). 
Single colonies from the sample plates were grown in 1ml of LA supplemented with 100 
µg/ml of Amp, overnight and then miniprepped using the Fermentas plasmid kit. The 
miniprepped DNA was then further analysed by digesting with Pst I and run on a 0.8% 
agarose gel to confirm the presence of the insert. The DNA was sent off for sequencing at 
Inqaba Biotec using the M13 forward and reverse primers.  
 
 
4. 1 Sequence analysis 
 
This was done using the National Centre of Biotechnology Information online database 
(http://www.ncbi.nlm.nih.gov/) and the FASTA, BLASTN, BLASTX2 tools found on that 
website and NEBCUTTER tools (http://tools.neb.com/NEBcutter2/index.php).  
 
 
 
5.0 Construction of a restriction map 
 
DNA to be mapped was digested using various enzymes. Enzymes that cut the DNA once or 
twice were used to construct the map. Single digests were compared with double digests of 
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the DNA. All digestions were run on 0.4% agarose for larger fragments (>2kbp) and 0.8% 
gels for the smaller fragments (<2kbp). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
CHAPTER 4 
               RESULTS 
 
4.1 Selection of spontaneous mutants of Mycobacterium smegmatis DSM 43756 and 
Mycobacterium smegmatis 43756Km1  
 
      
Figure 6: Growth of Mycobacterium smegmatis 43756Km1 and Mycobacterium smegmatis 
DSM 43756 on: A- BHI agar, B- BHI agar (20 µg/ml rifampicin) and C-BHI agar (100 µg/ml 
kanamycin).  
 
The first step in this project was to generate spontaneous mutants of M. smegmatis 
43756Km1 and M. smegmatis DSM 43756 which were resistant to high levels of rifampicin. 
This is because inactivation is more readily observable at high level rifampicin 
concentrations. Inactivation through ribosylation is not possible in Mycobacterium smegmatis 
43756Km1, which is a mutant of Mycobacterium smegmatis DSM 43756 made by disrupting 
the arr gene with a Kan
R
 cassette (Quan et al. 1997). Therefore, Mycobacterium smegmatis 
43756Km1 is sensitive to Rif but resistant to Kan Figure 6B and 6C respectively. Once the 
spontaneous mutants of M. smegmatis 43756Km1 and M. smegmatis DSM 43756 were 
generated Rif inactivation assays were carried out.  
 
 
 39 
4.2 In-vitro assays 
 
The ability of the two strains to inactivate rifampicin was investigated through in-vitro 
assays. The M. smegmatis 43756Km1 and M. smegmatis DSM 43756 mutants were grown in 
BHI overnight at 37ºC. 50 µl of each culture was added to 5 ml of BHI and grown for 3 hrs 
after which Rif was added to final concentration 20 µg/ml. Aliquots were taken at 24 hrs, 48 
hrs and 72 hrs and added to wells made on ½ LA plates, stored at 4ºC for 4 hrs and these 
were incubated overnight at 37ºC. The assay organism used was Bacillus subtilis 1A3. Two 
sets of assay tests were set up, to one 0.05 % Tween 80 was added to the cultures and to 
another 4 beads were added to cultures, this being done to minimise clumping of 
mycobacterial cells. Tween 80 is known to slow down growth, the test using beads was done 
as a control so as to check whether Tween 80 significantly affected the way in which 
rifampicin was inactivated by the microorganisms. The mutant strain, M. smegmatis 
43756Km1, is expected to inactivate rifampicin faster than the parental strain because there  
is a higher probability that the inhibitory effects of rifampicin are absent in the mutant.   
 
Samples of the supernatants were assayed at 24, 48 and 72 hrs to check for Rif inactivation.  
Two negative controls were set up, BHI with 20 µg/ml of Rif (no cells) and BHI with 20 
µg/ml Rif inoculated with Rhodococcus rhodochrous Ri8.   
 
 
Figure 7: In-vitro assays; test organisms grown in the presence of Tween 80 (K- M. 
smegmatis 43756Km1, C- control, R- R. rhodochrous Ri8 and 4- M. smegmatis DSM 43756).  
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At 24 hrs both tests (Figure 7 and 8) showed similar sized zones of inhibition, at 48 hrs in the 
bead test the zone of inhibition was almost completely gone around M. smegmatis 43756Km1 
whilst in presence of Tween 80 test it was present but had reduced in size compared with that 
at 24 hrs. At 72 hrs in the bead test (Figure 8) the zones of inhibition were completely absent 
around both the M. smegmatis 43756Km1 and M. smegmatis DSM 43756 wells whilst in the 
Tween 80 medium only the M. smegmatis DSM 43756 was completely gone and the M. 
smegmatis 43756Km1 was reduced in size. Therefore complete inactivation of Rif occurred 
for both the M. smegmatis 43756Km1 and the M. smegmatis DSM 43756 strains at 72 hrs in 
the bead test. However inactivation was retarded by Tween 80 with complete inactivation for 
M. smegmatis DSM 43756 at 72 hrs and of M. smegmatis 43756Km1 at 80 hrs. R. 
rhodochrous Ri8 does not inactivate Rif at all so a zone of inhibition was expected, as well as 
around the cell-free negative control. 
 
Figure 5: In-vitro assays; test organisms grown in the presence of beads (K- M. smegmatis 
43756Km1, C- control, R- R. rhodochrous Ri8 and 4- M. smegmatis DSM 43756).  
 
 
4.3 Genomic library construction in E. coli  
 
 A genomic library is a collection of cloned fragments of genomic DNA inserted into a 
cloning vector. These clones are stored and propagated in a population of micro-organisms 
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(host) through the process of molecular cloning. The purpose of creating a genomic library is 
to investigate entire structures of genes and to study regulation of gene expression. This is 
also essential for genetic transformation. In this project a genomic library was generated so as 
to study gene expression as regards to rifampicin resistance. 
         
 
4.3.1 Determination of restriction enzyme for the genomic library  
 
Twelve restriction enzymes were tested as candidates for the genomic library construction of 
M. smegmatis 43756Km1 as shown in Figure 9. The enzyme to be used was determined by 
its frequency of cutting genomic DNA as well as possessing a restriction site in the plasmid 
to be used which was pDA71-1.  Xba I was determined to be the most suitable for 
construction of the genomic library. However, after ligating the digested M. smegmatis 
43756Km1 genomic DNA to the Xba I digested pDA71-1 plasmid it was noted that the 
transformation and ligation efficiency was very low, as noted by the growth of very few 
transformants. Consequently, the cloning vector was changed to pDA71 and the restriction 
enzyme used was Pst I. Since Pst I was a frequent cutter of this genomic DNA a partial Pst I 
library was constructed. 
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Figure 6: Determination of the restriction enzyme to be used for library construction; 
electrophoresed on a 0.4% agarose gel. M. smegmatis 43756Km1 after digestion with X MA 
JI (Lane 4), Bam HI (5), Bgl II (6), Hind III (7), Sau 3A (8), Nhe I (9), Nsi I (10), Pst I (11), 
Sfu I (12), Xba I (13), Xho II (14), Xmi I (15).  Lane 1– molecular weight marker, Lane 3– 
undigested DNA. 
 
 
The partial library was generated by diluting the Pst I enzyme ×4, ×16, ×64, ×128, ×256 and 
adding 0.5 µl of each dilution to 10 µl of genomic DNA and incubating at 37ºC overnight. 
From Figure 10, a dilution of between ×64 and ×128 was used for the library construction. 
At this dilution the genomic DNA will not be cut too frequently producing small fragments or 
cut infrequently producing larger fragments which were too large. 
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Figure 7: Determination of the dilution for a partial Pst I digestion of genomic DNA from M. 
smegmatis 43756Km1; electrophoresed on a 0.4% agarose gel. Lane 1- molecular weight 
marker; Lanes 3-9, Pst I dilution factor: ×4, ×16, ×64, undiluted Pst I, ×128, ×256 AND X96 
respectively. 
 
 
4.3.2 Calculation of number of clones 
 
Screening minipreps of clones digested with Pst I the average insert size was found to be a 
~2.9 kbp. The frequency of detectible inserts was determined to be ~60%, (Figure 11).  
According to the National Centre for Biotechnology Information (NCBI) the complete 
genome of M. smegmatis is 6 988 209 nucleotides. This number was used to calculate the 
number of clones required using the Clarke-Carbon formula.  
 
Approximately 13 600 transformants with the recombinant vector DNA (pDA71 + genomic 
DNA) were washed off the plates using LB supplemented with 100 µg/ml of Amp and were 
pooled together to create a genomic library with a ≥95% probability of carrying a particular 
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DNA. Aliquots were stored at -20ºC and 200 µl was inoculated into 200 ml of LB in order to 
do a bulk extraction of the library.  
 
                              
    
Figure 8: Plasmid screen of recombinant pDA71 vectors digested with Pst I; electrophoresed 
on a 0.8% agarose gel. Lane 1: molecular weight marker, Lanes 3-12: digested recombinant 
vectors. 
 
 
4.4 Susceptibility of Rhodococcus strains to different antibiotics 
 
A possible host strain for the expression of the genomic library was investigated from various 
Rhodococcus strains. The ideal strain to be used as a host or recipient of the library DNA 
would have to be sensitive to Rif (≥100 ng/ml) and sensitive to 40 µg/ml Cam. A 
Rhodococcus strain unable to inactivate rifampicin was used as the recipient strain since the 
objective of the experiment was isolating a clone which inactivated Rif based on it conferring 
Rif resistance. Once the recombinant pDA71 clone is transformed into this Rhodococcus 
strain it should be able to inactivate Rif if it contains the gene responsible for inactivation and 
vice versa. This recipient strain must be inhibited by 40 µg/ml of Cam as this is the 
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concentration at which pDA71 confers resistance in Rhodococcus strains. A number of 
Rhodococcus strains were tested for Rif and Cam sensitivity Figure 12. 
 
  
Figure 9: MICs of potential host strains of Rhodococcus 
 
Unfortunately all six were insufficiently sensitive to Rif. However Susan Andersen in her 
work had made some highly sensitive (Hs) strains of R. rhodochrous to Rif; these were tested 
for their respective MICs to Rif and Cam, Figure 13 and 14.  
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        Figure 10: Determination of rifampicin MICs of Rhodococcus erythropolis strains. 
 
Since Hs7 was more sensitive (100 ng/ml) to Rif than the rest of the strains it was chosen to 
be the recipient strain of the library. Cultures of Hs7 were grown in 1-4% of LBSG to 
determine which concentration of glycine was best suited to the growth of the organism. It 
was determined to be 3%. 
 
  
          Figure 11: Determination of chloramphenicol MICs of Rhodococcus strains. 
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As an additional marker Hs7-1 was made resistant to 100 µg/ml Nal. This mutant was 
designated Hs7-1. Hs7-1 had very low transformation efficiency and to confirm it was 
actually a Rhodococcus species, a phage plaquing test was done (section 3.5). The phages 
used, K04 and W12, were isolated from R. erythropolis SQ1 (Shibayama, 2006) and they 
only produce plaques in the presence of Rhodococcus species. Presence of plaques confirmed 
that Hs7-1 was indeed a rhodococcal strain, Figure 15.  
     
Figure 125: Phage spotting tests with A- R. erythropolis SQ1 and B- R.  erythropolis Hs7-
1m 
 
 
4.4.1 Plasmid curing 
 
To enhance transformation efficiency of Hs7-1 it was transformed with the pDA71*, 
selection being for chloramphenicol resistance. Resultant colonies were then grown in the 
presence of 1% Ethidium bromide (EtBr) but absence of Cam to cure the plasmid and 
streaked out into single colonies on LA plates. Plasmid curing is a process of completely 
removing or displacing plasmids from bacteria. This is usually achieved by introducing stress 
to the bacteria in some way, for example by growing at: high temperatures, or in the presence 
of a detergent, mutagens or some other DNA modulating agents, such as intercalating agents 
(ethidium bromide, acriflavin or acridine orange). Plasmids are non-essential, except under 
certain conditions, such as when an antibiotic is present. However, naturally occurring 
plasmids tend to be very stable as they have managed to survive selective pressure over 
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millions of years. Hence, to find out what property they confer on the bacterium that carries 
them, it is essential to displace them to produce bacteria that lack the plasmid so that bacteria 
with and without the plasmid can be compared. 
 
The single colonies of the EtBr treated Hs7-1 were then patched onto an LA Cam 40 µg/ml 
plate and on LA. The untreated Hs7-1 without the cloned DNA and Hs7-1 that contained the 
cloned DNA were used as controls. All of these were expected to grow on LA but only the 
Hs7-1 with the cloned DNA is expected to produce growth on Cam 40 µg/ml. Which was 
what was observed with the results obtained. Of the colonies of the Hs7-1 that had undergone 
EtBr treatment, those which were able to grow on Cam plates were named Hs7-11. Upon 
transformation with the cloned DNA these cells had an increased ability to take up the cloned 
DNA as shown by the increased number of transformants. 
      
Plasmid curing is usually stressful to the host, and most bacteria respond by increasing the 
mutation rate. This can result in alteration of the host's phenotype irrespective of whether the 
plasmid has been displaced or not, thereby seriously undermining the conclusions that can be 
drawn. Therefore, six mutants of Hs7-11 were patched onto Rif 100-700 ng/ml to check 
whether the procedure had affected the Rif MIC. Two of the mutants (#2 and #3) had an MIC 
of 200 ng/ml, mutant # 4 an MIC of 700 ng/ml and the rest 100ng/ml (Figure 16). A Hs7-11 
mutant that still had the same MIC as the parental Hs7, i.e. 100ng/ml of Rif, was used as a 
host for the library of M. smegmatis 43756Km1-E. coli. 
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     Figure 136: Determination of rifampicin MICs for the R. rhodochrous Hs7-11 mutants.  
4.4.2 Screening of the Hs7-11 library 
 
After transformation into Hs7-11 this library was pooled into LA and grown in the presence 
of 40 µg/ml Cam. Aliquots were tested for the presence of clones with an increased Rif MIC 
however in no case was plasmid-borne resistance detected. 
 
 
4.5 Rifampicin resistance in E. coli  
 
The reason why a clone conferring rifampicin resistance could not be found in R. 
rhodochrous Hs7-11 could probably be because this strain expressed very low levels of the 
heterologous protein responsible for resistance. An alternative approach which was done in 
this project was to screen the library for Rif resistance heterologously expressed in E. coli. 
This bacterium was decided upon as an alternative host because it is the most widely 
employed host used in heterologous expression systems. Its popularity is due to the vast body 
of knowledge about its genetics, complete genomic sequence and high growth rates combined 
with its ability to express high levels of heterologous proteins, i.e. strains producing up to 
30% of their total protein as the expressed gene product, result in high volumetric 
productivity (Rai and Padh, 2001).  It however poses significant problems in post-
translational modifications of proteins, as E. coli has no capacity to glycosylate proteins in 
either N- or O-linked conformation. This fact is not relevant in this project so it will not be 
discussed further. A number of clones with Rif resistance were detected this way (Figure 17). 
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Figure 17: Plasmid screen of recombinant pDA71 vectors of E. coli clones digested with Pst 
I; electrophoresed on a 0.8% agarose gel. Lane 1: molecular weight marker, Lanes 3-12: 
digested recombinant vectors. 
 
Ten of these clones were digested and six of the ten digested recombinant vectors had inserts 
(Figure 17) and these were named p6, p7, p8, p9, p10 and p11 respectively. These clones 
were different in size as noted by their different restriction patterns. However, some of the 
clones had inserts of the same apparent size. A common 3.0 kbp fragment was observed for 
both the p6 and p10 clones, but p10 had another 0.5 kbp fragment as well. A fragment of 0.7 
kbp was also observed in both p8 and p11 although p8 had two more fragments (5.0 and 1.0 
kbp) which it did not share with p11. These clones were then retransformed into E. coli 
MM294-4 and selected for on Amp 100 and Rif 20 µg/ml plates. This marker rescue 
procedure was to check whether the resistance to Rif was plasmid borne or not. E. coli 
carrying pDA71* was used as a control and had a Rif MIC of ≤7 µg/ml. 
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4.6 Determination of the recombinant E.coli rif-resistant clones rifampicin MICs 
 
The 6 clones together with pDA71* were grown on LA Amp overnight and individual 
colonies were picked up and inoculated into a replica plating plate containing 250 µl of LB 
per well. A replicator was used to plate these on Amp 100 and Rif (20-400 µg/ml) plates 
from the higher antibiotic concentration to the lowest. These were incubated for 24 hrs at 
37ºC. Five (p6, p7, p8, p9, p10 and p11,) had varying MICs ranging from 20-50 µg/ml and 
only p7 (renamed pTM1), had an MIC of >400 µg/ml of Rif, Figure 18.  
  
   
                   Figure 14: MICs of the 6 clones identified by marker rescue. 
 
Clones pTM1 and p6 which had the highest Rif MICs were also tested on other antibiotics to 
check whether they had altered MICs. Plasmid pDA71* was again the control. These were 
tetracycline, kanamycin, chloramphenicol, spectinomycin, streptomycin, and erythromycin, 
Figure 19.  For Kan, Spc and Tet the MIC of both pTM1 and pDA71* was the same and p6 
was either slightly higher or lower as compared to them. A modest difference in MIC was 
found with Ery: the MIC was ~40% higher for pTM1. 
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                          Figure 15: MICs with respect to other antibiotics.  
 
 
 
4.7 Phenotypic characterization of M. smegmatis rifampicin resistant clone 
 
The effect of temperature and pH was tested so as to characterize the best growth conditions 
of the clone.  E. coli MM294-4 transformants were used for determining effect of pH on 
rifampicin resistance. 
 
 
4.7.1 Effect of temperature on rifampicin resistance  
 
E. coli MM294-4 cells transformed with pTM1 was spotted onto LA Rif plates (50-400 
µg/ml) and incubated at 28ºC, 37ºC  and 42ºC for 24 hrs. The results indicated that at lower 
temperatures resistance was reduced, Table 7. At 28ºC its MIC dropped to 300 µg/ml of Rif. 
But at 37ºC and 42ºC MIC was ≥400 µg/ml of Rif though at 42ºC it there was slightly less 
growth compared to that at 37ºC.  
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Table 7: Effect of temperature on Rif resistance. 
MIC 
ug/ml rif 
                                           T (ºC) 
           28               37              42  
50 ++++ ++++ ++++ 
100 ++++ ++++ ++++ 
150 +++ ++++ ++++ 
200 +++ ++++ ++++ 
250 ++ +++ +++ 
300 - +++ +++ 
350 - +++ ++ 
400 - +++ + 
 
++++ confluent growth +++ pronounced growth ++ growth    
+ sparse growth     - no growth 
 
 
 
 
 
4.7.2 Effect of pH on rifampicin resistance  
 
Plates used in these tests were standard LA plates whose pH had been adjusted to 5.5 using 
HCL or 8.5 with NAOH. The control being standard LA plates whose pH has not been 
altered, these have a more neutral pH. The results indicated that resistance was highest at 
neutral pH and lowest at acidic pH.  There was no significant difference on the growth of E. 
coli MM294-4 cells transformed with pTM1 on Rif 150-400 µg/ml of Rif at both pHs. 
However, at a pH of 8.5 the growth was a bit more pronounced than at 5.5, Table 8. At 
alkaline pH, the vector only control grew at higher concentrations of rifampicin than it did at 
acidic or neutral pH. 
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Table 8: Effect of pH on Rif resistance. 
 
Rif µg\ml 
                                             pH 
                 7.0               5.5                8.5 
100 ++++ +++ ++++ 
200 ++++ +++ +++ 
300 +++ ++ +++ 
400 ++ + + 
 
++++ confluent growth +++ pronounced growth ++ growth    
+ sparse growth     - no growth 
   
 
 
4.8 Cloning and sequencing 
 
Since pTM1 conferred a Rif MIC of above 400 ug/ml it was selected for sequencing and 
cloned into pUC18 and pUC19. Both the clone and the vectors had very few compatible 
restriction sites. Since the Pst I site was in both, it was used for cloning. Upon digestion with 
Pst I it produced 2 fragments with a total size of 2.5 kbp, Appendix A. Partial Pst I 
digestions of the clone were done so as to produce a larger single fragment that possessed 
both the 2 smaller ones as one piece. Once pTM1 was ligated into these 2 plasmids it was 
sent for sequencing at Inqaba Biotech. M13 forward and reverse primers were used for 
sequencing and the sequence below was shown to be derived through processing with the 
M13 reverse primer. 
 
 
 
4.8.1.1 Analysis of sequenced DNA 
 
This sequence showed a 63% G-C content which is in line with expected results of currently 
documented complete genomic sequences of mycobacterial DNA which is high in G-C 
nucleotides as well. When the nucleotide sequence was subjected to a BLAST analysis, it 
showed 100% Max identity to M. smegmatis mc
2 
155 and had an E value of 0.00. 
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4.8.1.2 Detection of ORF 
 
For the detection of ORFs, 2 programmes were utilised: NEBCUTTER and GeneMark. Both 
of these programs identified the same ORF. Using the NEBCUTTER program the ORF 
identified (Figure 20), was 394 aa long, flanked with Xho I and Eco RV sites whilst using the 
GeneMark program, it was shown to be 369 aa long. To further verify the result of these 
translation programs, a comparison of the above ORF’s was done using BLASTn (NCBI) and 
the ExPASy Proteomics server (Swisprot). They showed significantly similar results and that 
the ORF was 394 aa. The ExPASY server had a score of 589 and an E value of 2×10
-166
 for 
2-hydroxy-6-ketonona-2,4-dienedioic acid hydrolase whilst that of the BLASTn was 599 and 
E-value of 2×10
-169
 respectively. Both confirming that 2-hydroxy-6-ketonona-2,4-dienedioic 
acid hydrolase from M. smegmatis  was encoded by this clone. This enzyme has been 
reported by KEGG (Kyoto Encyclopedia of Genes and Genomes) to take part in the 
catabolism of aromatic compounds by acting on carbon-carbon bonds in ketonic substances. 
The gene for this enzyme was named rdn (rifampicin decompostion).  
 
 
 
Figure 16: rdn predicted ORF. 
 
4.8.1.3 Comparison between rdn and iri  
 
The inactivation mechanism of Rif through decomposition was first discovered in R. equi and 
since a similar gene was being tested for in M. smegmatis 43756Km1 a comparison was done 
between the iri gene and the rdn gene sequences. The amino acid sequences of both genes 
were inputted into BLASTp and compared, only one hit was found. The blast results showed 
that there was a significant similarity between the two gene sequences over a query coverage 
of 60% (with an E value of 0.50). Unfortunately, that one hit was for an unnamed protein 106 
amino acids long (Appendix B) and search on NCBI and Swiss-Prot revealed no further 
information concerning this protein. Therefore we can conclude that though these two genes 
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products have a similar property of inactivating rifampicin they show no major shared 
features as regards sequence. A similar disparity was previously shown between iri, arr, and 
grt (Quan et al, 1997; C Lephoto, unpublished). 
 
 
4.8.1.4 Comparison of rdn and arr  
 
A similar BLAST as above was done as well with the rdn and arr genes. M. smegmatis 
43756Km1 is a mutant of M. smegmatis 43756 but it has the arr gene disrupted by a Kana
R 
cassette. This prevents a functional ADP-ribosyltransferase being produced and therefore 
inactivation of Rif by ribosylation is prevented. The alternative inactivation method may still 
be utilised, in this case is decomposition. The comparison between arr and rdn showed that 
there was no significant similarity between the two. 
 
 
4.8.2 Analysis of protein parameters 
 
The translated sequences were used as the input sequences to conduct an analysis of the 
protein parameters using the ProtPar (protein parameters) and ProtScale (protein scale) 
programmes from the ExPASy engine. From the data shown in Table 9, the total number of 
positively charged residues, arginine and lysine was 53 (13.3%) while that of negatively 
charged residues, glutamic acid and aspartic acid was determined to be 41 (10.4%).  
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Table 9: Protein parameters of the rdn protein (hydrolase) as determined by the ProtPar 
programme 
 
Number of amino acids: 394.      Molecular weight: 43187.3.            Theoretical pI: 9.68 
 
Amino acid composition:      
Amino Acid  Symbol Number           % composition 
Alanine  (A)  43   10.9% 
Arginine  (R)   41   10.4% 
Asparagine  (N)    9    2.3% 
Aspartic acid  (D)   20    5.1% 
Cysteine  (C)    6    1.5% 
Glycine  (Q)   16    4.1% 
Glutamic acid  (E)   21    5.3% 
Glycine  (G)   42   10.7% 
Histidine  (H)   15    3.8% 
Isoleucine  (I)   12    3.0% 
Leucine  (L)   39    9.9% 
Lysine  (K)   12    3.0% 
Methionine  (M)    8    2.0% 
Phenylalanine  (F)   16    4.1% 
Proline  (P)   23    5.8% 
Serine  (S)   17    4.3% 
Threonine  (T)   17    4.3% 
Tryptophan  (W)    4    1.0% 
Tyrosine  (Y)    6    1.5% 
Valine  (V)   27    6.9% 
Pyrrolysine  (O)    0    0.0% 
Selenocysteine  (U)    0    0.0% 
 
Total number of negatively charged residues (Asp + Glu): 41 
Total number of positively charged residues (Arg + Lys): 53 
The N-terminal of the sequence considered is M (Met). 
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These protein parameters were used to investigate some properties of the protein. The first of 
which was the protein’s hydrophobic\ hydrophilic characteristics. This information can be 
used to suggest the cellular localization of this protein. The Kyte and Doolittle scale of 
hydropathic characteristics of the twenty amino acids was used to plot a hydrophobicity plot 
(Figure 25) of rdn protein. In the plot, hydrophobic amino acids have a positive value whilst 
the hydrophilic a negative value.  
 
Figure 17: Kyte-Doolittle hydrophilicity plot for the hydropathic characteristics of rdn 
protein. The x-axis shows amino acid numbers. 
 
An amino acid window of 50 was used to plot the graph and showed a maximum 
hydrophobic protein of 1.6 and a minimum hydrophilic protein of -3. According to Figure 
21, the rdn protein is primarily hydrophobic in nature with one large hydrophilic region 
spanning amino acids ~5- 60. 
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4.8.3 Gram staining 
 
Dabbs et al., (2003) discovered through light microscopy studies that E. coli cells 
transformed with a plasmid carrying the arr gene are filamentous rather than coliform. This 
could be because the arr gene product is involved in bacterial wall biosynthesis and when 
over-expressed leads to an altered cell morphology. Whereas those transformed with the 
vector only were normal. This was not the case when rdn was transformed into E. coli; it did 
not show any altered cell morphology Figure 22. 
 
   
   Figure 182: Gram stains of transformants. 
 
 
4.8.4 Inactivation assays with rdn 
 
The clone was transformed into M. smegmatis mc
2 
155 and in-vitro assays were conducted to 
check whether rdn was responsible for the inactivation of rifampicin, since this strain lacks 
the ability to inactivate Rif. This was done by first digesting pTM1 with Pst I and ligating the 
resultant fragment into M. smegmatis shuttle vector, pNV18. The resultant clone was named 
pTM2 and it was then transformed into M. smegmatis mc
2 
155. The controls were M. 
smegmatis 43756Km1 (K) and M. smegmatis DSM 43756 (4) and BHI with 20 µg/ml Rif. At 
24 hrs zones of inhibition could be detected around all of the test assays but at 48 hrs M. 
smegmatis 43756Km1 had inactivated rifampicin as seen by the absence of the zone of 
inhibition. At 48 hrs as well, there was a reduction in the zones of inhibition around the rest 
except the negative control and M. smegmatis DSM 43756 showing that inactivation was 
occurring though at a slow rate. At 72 hrs no zones of inhibition could be detected around M. 
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smegmatis mc
2 
155 (mc4 and mc7).  These results showed that the M. smegmatis mc
2 
155 
(mc4 and mc7) when transformed with pTM2 inactivated the antibiotic but at a very slow rate 
as compared to the rate of inactivation in M. smegmatis 43756Km1, Figure 23.  
 
  
Figure 193: Assays of Mycobacterium smegmatis mc
2 
155 transformed with pTM2. K- 
Mycobacterium smegmatis 43756Km1, 4- Mycobacterium smegmatis DSM 43756, mc4- 
Mycobacterium smegmatis mc
2
 155+pTM2 and mc7- Mycobacterium smegmatis mc
2 
155+ 
pTM2. 
 
 
4.8.5 Decolourisation tests with rdn 
 
The decolourisation of rifampicin is the main characteristic observed in the inactivation of 
this drug through decomposition. The purpose of this test was to check if rdn decolourised 
this antibiotic as well. Spectrophotometric tests were also carried out in tandem with the 
above assays to test for the decolourisation of Rif. The absorbance of the supernatant of the 
above cultures was measured at the time (48 hrs) where complete inactivation was seen, 
Figure 23, at a wavelength of 560 nm. Percentage decolourisation was calculated using the 
following formula: 
   % Decolourisation =   A0-A    x 100 
       A0 
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The test showed that the rdn product decolourised Rif by 75% unlike iri protein which 
completely decolourised Rif. The slower inactivation noted in the assay test above could be 
because Rif is not totally broken down by the rdn enzyme. 
 
4.9 Location of the rifampicin enzyme 
 
Tests were done to investigate the location of the enzymatic activity responsible for the 
inactivation of rifampicin. To do this the extracellular fraction (culture broth and EDTA 
treatments), and the cell bound fraction were separated. At 72 hrs the zones around the cell 
bound fraction of M. smegmatis 43756Km1 and M. smegmatis DSM 43756 had not 
significantly reduced in size suggesting that the enzyme responsible for the inactivation of 
rifampicin was absent from this fraction, Figure 24. But the zone of inhibition was abolished 
for the extracellular fraction of M. smegmatis 43756Km1 (K) and the one around M. 
smegmatis DSM 43756 (4) had reduced in size. This indicated the enzyme may be released 
from the cells into the growth media so this 2-hydroxy-6-ketonona-2, 4-dienedioic acid 
hydrolase may have an extracellular function.  
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Figure 20: Enzyme distribution assays, CB- cell bound fraction, EF- extracellular fraction 
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CHAPTER 5  
DISCUSSION 
 
5.1 Hydrolases 
 
The enzyme, 2-hydroxy-6-ketonona-2, 4-dienedioic acid hydrolase, discovered to be 
responsible for rifampicin resistance belongs to a family of enzymes called hydrolases. 
Hydrolases are related to monooxygenases in that they both catalyze oxidoreductase reactions 
however; monooxygenases are cofactor–dependent enzymes whilst hydrolases are not. 
Hydrolases are part of the monooxygenase family. 
 
S + O2 +XH2= SO + X + H2O   or     SH2 +O2 = SO + H2O   (monooxygenases) 
   
A–B + H2O → A–OH + B–H      (hydrolases) 
 
Hydrolases can be further classified into several subclasses, based upon the bonds they act 
upon; i.e. esterases, DNA glycosylases, proteases and helicases. These enzymes catalyze the 
hydrolysis of proteins, nucleic acids, starch, fats, phosphate esters and other macromolecular 
substances or of various chemical bonds. In simpler terms they catalyze the hydrolysis of 
chemical bonds (-O, C-N, C-C and phosphoric anhydride bonds) with the addition of H2O. 
The enzyme, 2-hydroxy-6-ketonona-2,4-dienedioic acid hydrolase is believed to play a part 
in the hydrolysis of phenylpropionate by hydrolysing C-C and –O bonds. 
 
 
 
5.1.2 2-Hydroxy-6-ketonona-2, 4-dienedioic acid hydrolase  
 
The 394 amino acid long ORF (rdn) discovered on the pTM1 clone from M. smegmatis 
43756Kml codes for the enzyme 2-hydroxy-6-ketonona-2,4-dienedioic acid hydrolase [EC: 
3.7.1-]. It was discovered that in E. coli it takes part in the phenylpropionate degradation 
pathway and that it is a 62 kDa homodimeric enzyme. This hydrolase belongs to the mhpC 
alpha/beta hydrolase family, mhpC gene codes for a number of enzymes which can degrade 
m-hydroxyphenyl propionic acid. The enzyme 2-hydroxy-6-ketonona-2,4-dienedioic acid 
hydrolase is part of the multidomain esterase-lipase superfamily.  
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The gene for this enzyme is found from position 6 103 557 - 6 104 435 on the complete 
genome of M. smegmatis mc
2 
155. It lies between a gene for biphenyl-2,3-diol 1,2-
dioxygenase and for a pigment production hydroxylase. All 3 genes as well as for 
nitrilotriacetate monooxygenase component B share the same operon. Biphenyl-2,3-diol 1,2-
dioxygenase plays a role in the degradation of biphenyl whilst nitrilotriacetate 
monooxygenase component B and the pigment production hyroxylase are thought to take part 
in xenobiotics degradation and metabolism. 2-hydroxy-6-ketonona-2,4-dienedioic acid 
hydrolase is involved in aromatic compound catabolic processes meaning its chemical 
reactions and pathways result in the breakdown of any substance containing an aromatic 
carbon ring and in phenylalanine metabolism.  
 
I hypothesize that this enzyme attacks the naphthoquinoid ring of Rif which results in its 
inactivation (Figure 25). Since 2-hydroxy-6-ketonona-2,4-dienedioic acid hydrolase is 
known to hydrolyse ketoic compounds I postulate that it might break down Rif at the C11. 
        
 
Figure 25: Rifampicin, positions of inactivation; C21, C23 and the naphthalene moiety 
 
This enzyme takes part in a number of different reactions some of which are shown below: 
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2-Hydroxy-2,4-pentadienoate  + Succinate <=> 2-Hydroxy-6-oxonona-2,4-diene-1,9-dioate + 
H2O  
 
6-Oxo-2-hydroxy-7-(4'-chlorophenyl)-3,8,8-trichloroocta-2E,4E,7E-trienoate + H2O <=> 2-
(4'-Chlorophenyl)-3,3-dichloropropenoate + 2-Hydroxy-3-chloropenta-2,4-dienoate  
 
6-Ketoxycyclohex-1-ene-1-carboxyl-CoA + 2 H2O <=> 3-Hydroxypimeloyl-CoA  
 
2,6-Dihydroxypseudooxynicotine + H2O <=> 2,6-Dihydroxypyridine + 4-
Methylaminobutyrate  
 
 Some of the mechanisms of action are shown below, Figure 26. These reactions as well as 
well as some of the above show possible hydrolysis of –O bonds in various molecules which 
are similar in structure to rifampicin. 
 66 
 
Figure 21: Possible mechanisms of action of 2-hydroxy-6-ketonona-2,4-dienedioic acid 
hydrolase 
 
Also amongst the substrates catalysed by this enzyme are: glycolate; pyruvate; 2-hydroxy-
2,4-pentadienoate;  succinate; 4-carboxy-2-hydroxymuconate semialdehyde; acetate; 6-oxo-
2-hydroxy-7-(4'-chlorophenyl)-3,8,8-trichloroocta-2E,4E,7E-trienoate; 26-ketoxycyclohex-1-
ene-1-carboxyl-CoA 4-Isopropenyl-2-oxy-cyclohexanecarboxyl-CoA; 2-hydroxy-6-
ketononatrienedioate 2,6-Dihydroxypseudooxynicotine and  3D-(3,5/4)-
trihydroxycyclohexane-1,2-dione; showing that it has a broad spectrum of activity. 
 
 
 
5.5 Cell morphology 
 
According to Dabbs et al., 2003, it was discovered that if the arr protein is involved in 
bacterial wall biosynthesis, its over-expression alters cell morphology. Light microscope 
visualization of E. coli cultures revealed those transformed with plasmid with the arr gene 
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became filamentous whilst those with the vector only were normal. When rdn was 
transformed into E. coli in this work there was no evidence of the E. coli becoming 
filamentous. Apart from altered Rif phenotype (and to a much lesser extent Ery) no other 
phenotypic differences were observed between cells transformed with pTM1 and those of the 
parental strain. 
 
In conclusion of this work, 2-hydroxy-6-ketonona-2,4-dienedioic acid hydrolase was found to 
be responsible for the inactivation of rifampicin. However, unlike the monooxygenase -like 
enzyme discovered in R. equi this enzyme slowly breaks down but does not completely 
breakdown rifampicin as evidenced by the incomplete decolourisation. Future projects can 
look into the actual mechanisms of action of 2-hydroxy-6-ketonona-2,4-dienedioic acid 
hydrolase in the inactivation of rifampicin as well as the products produced in the process. 
Comparison between these 2 related enzymes can also be done to determine how their 
enzymatic functions differ from each other. 
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CHAPTER 5 
         APPENDICES 
 
5.1 APPENDIX A: pTM1 clone complete sequence. 
 
The brown sequence codes for 2-  hydroxy-6-ketonona-2,4-dienedioic acid hydrolase. 
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5. 2 APPENDIX B: BLASTp comparison of rdn and iri. 
 
Sequences producing significant alignments:  
Accession          Description   Total score  Query coverage         E value  
 62581             unnamed protein product          117                          60%                   0.50 
 
 
Alignments 
 
unnamed protein product of length=479 
 
Score = 18.5 bits (36),  Expect = 0.50, Method: Compositional matrix adjust. 
 Identities = 19/107 (17%), Positives = 37/107 (34%), Gaps = 20/107 (18%) 
 
Qry89         QPRIRSSARGHDGLMVTATQEITFESTSRFADVQAGELAMRLHYHEAGDP     138 
                     Q  + S+A G   +    ++ + FE   R+   +   +++R  + E  D            
Sbjct 339  
QAELISTAAGPQAVRRLISELMEFEDVKRYLTEKITAISIRYDFGEGDDLLGRRLRNIAL                
398 
 
Query  139  ----------SAQTIVLLHGGGPGAASWSNFGRNIAVLAEHFHVLAV  175 
                                S + ++L  GG      WS+   +I   +      AV 
Sbjct  399                TRGNLYDLMRSGRGLLLDQGGQLSVDGWSDRADHIVDTSTELEAPAV  
445 
 
 
 
 Score = 18.1 bits (35),  Expect = 0.64, Method: Compositional matrix adjust. 
 Identities = 7/13 (53%), Positives = 9/13 (69%), Gaps = 0/13 (0%) 
 
Query  7    KRGRGIRTAQGGQ  19 
                  + GRG+   QGGQ 
Sbjct  408  RSGRGLLLDQGGQ  420 
 
 
 Score = 17.7 bits (34),  Expect = 0.74, Method: Compositional matrix adjust. 
 Identities = 10/22 (45%), Positives = 10/22 (45%), Gaps = 0/22 (0%) 
 
 
Query  201  RGLLDHLGVEGRVPLLGNSLGG  222 
                    RGLLD     GR   LG    G 
Sbjct  56      RGLLDKFLAHGRKYPLGGFFAG  77 
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5.3 APPENDIX C: MEDIA 
 
Table 1: Composition of bacterial culture media 
Medium Components Components per 100 ml 
(Grams) 
 
           LB 
Tryptone 
Yeast extract 
 NaCl 
1 
0.5 
0.5 
          LB-agar Tryptone 
Yeast extract 
NaCl 
Agar (1.5% LB agar) 
1 
0.5 
0.5 
1.5 
           ½ LA Tryptone 
Yeast extract 
NaCl 
Agar 
1 
0.5 
0.5 
 0.75 
           BHI 
 
           BHI agar 
             Brain heart media 
 
             Brain heart media 
             Agar 
                  3.7 
 
3.7 
1.5 
            LBG LB agar (100 ml) + 
Glycine 
 
2% or 3% 
           LBSG LBG agar (100 ml)  + 
Sucrose 
 
10 
 
Medium Components Components per 250 ml 
(grams) 
 Regeneration 
media 
Tryptone 
Yeast extract 
NaCl 
3 
1.5 
0.9 
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Sucrose 
Glucose 
Technical agar 
 
 
 
 
0.25 TES 
1M CaCl2 
0.5% KH2PO4 
Nystatin 
 
 
 
  30.9 
1 
5.5 
After autoclaving the 
solution was cooled to 
60ºC and the following 
were added: 
 10 ml 
6 ml 
3 ml 
  1.5 ml 
Plates were dried at 37ºC 
for 2 days before use. 
 
100 ml of distilled water was added and this was mixed and autoclaved at 121°C for 20 min. 
Media was stored in the cold room at 4°C. 
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5.4 APPENDIX D: SOLUTIONS  
 
Table 2: Composition of solutions used for mini-plasmid preparations of E. coli 
Solution Composition of working solution 
 
Solution I 
            50 mM glucose 
25 mM Tris-HCl (pH 8) 
10 mM EDTA  
 
Solution II             0.2 M NaOH 
            1.0% SDS 
 
Solution III 
          
           60 ml 5M potassium acetate pH 4.8 
11.5 ml glacial acetic acid 
28.5 ml sterile dH2O 
 
Ribonuclease 
 
 
10 mg/ml solution in sterile dH2O, 
heated for 10 min at 95°C before 
use  
 
Distilled water was added to solutions I-III and autoclaved at 121°C for 20 min.  Solutions I, 
II, and ribonuclease were stored at -20°C and solution III in the cold room at 4°C.   
 
Table 3: Composition of solutions for E. coli CaCl2 transformation 
Solution Composition of working solution 
                   CaCl2 transformation 
                buffer 
 
            10 mM Tris-HCl 
100 mM CaCl2 
pH 7.5 
 
         20% glucose  
 
 
4 g glucose 
20 ml dH2O  
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100ml of distilled water was added, mixed and the solutions were autoclaved at 121°C for 20 
min.  Solutions were stored in the cold room (4°C).   
 
Table 4: Composition of solutions for Rhodococcus PEG mediated transformation 
Solution Composition of working solution 
                  Basal buffer (B)             10.3 g sucrose 
            25 mg K2SO4 
            202 mg MgCl2.6H20 
            10 ml 0.25M  pH 7.2 
            87.5 ml distilled water 
                 Protoplast buffer (P) 5 ml B buffer 
50 µl 0.5% KH2SO4 
125 µl 1M CaCl2 
                  1M CaCl2 21.9 g CaCl2 
100 ml distilled H2O 
                  0.5 % KH2SO4 0.5 g KH2SO4 
100 ml distilled H2O 
 
The basal buffer, 0.5 % KH2SO4 and 1M CaCl2 were autoclaved at 121°C for 20 min.  Only 
the basal buffer was stored at -20°C and the rest of the solutions were stored in the cold room 
(4°C).    
 
Table 5: Composition of agarose gel electrophoresis buffers for analysis of DNA 
 
Solution 
Composition of working solution 
Agarose gels 
 
0.4 g (0.4%), 0.8 g (0.8%) or 1.2 g 
(1.2%) agarose 
100 ml 0.5x TBE 
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TE buffer 2 ml 0.5 M EDTA pH 8.0 
1.0 ml 1M Tris-HCl pH 8.0  
97 ml dH2O 
Autoclaved at 121°C for 20 min.  
5x TBE 
 
            54.0 g Tris base 
27.5 g boric acid 
20 ml 0.5 M EDTA pH 8.0 
Added distilled water to 1 litre, mix and 
autoclaved at 121°C for 20 min.  
Running  
Buffer (0.5x TBE) 
25 ml 5x TBE 
225 ml sterile dH20 
25 µl EtBr  
 
 
Table 6: Composition of other solutions used in this work 
Solution Composition  
                          0.5M EDTA 
                    pH 8.0 
            18.6 g EDTA  
Adjust to pH 8 with 10 M NaOH 
Add 1 L water 
Autoclave (121°C, 20 min) 
               1.0M NaCl 5.8 g NaCl 
100 ml sterile dH20 
Autoclave (121°C, 20 min) 
                       Sodium Acetate 
pH 5.2  
408 g sodium acetate 
Adjust pH with 3M glacial acetic acid 
Add 1 L water  
Autoclave (121°C, 20 min) 
TE-saturated 
Phenol 
14 g phenol 
10 ml TE buffer 
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            1.0M Tris-HCl 
           pH 8.0 
24.2 g Tris base 
160 ml sterile dH2O  
Adjust to pH 8.0 
Top up to 200 ml  
Autoclave (121°C, 20 min) 
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5.5 APPENDIX E: ANTIMICROBIAL AGENTS STOCK SOLUTIONS 
  
 
Antibiotic Stock Concentration 
(mg/ml) 
Solvent 
Ampicillin 100 30% dH2O:70 % ethanol 
Chloramphenicol 20               ethanol 
Erythromycin 5 30% dH2O:70 % ethanol 
Kanamycin   10 sdH2O 
Nalidixic Acid   10 30% dH2O:70% ethanol 
Rifampicin   10                methanol 
Spectinomycin   20 sdH2O 
Streptomycin                   20 sdH2O 
Tetracycline                   10                methanol 
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5.7 APPENDIX F: PLASMIDS USED IN THIS WORK  
 
Restriction maps of plasmid pDA71 a Rhodococcus/ E. coli shuttle vector (adapted from 
Dabbs et al., 1995a).   
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Restriction map of plasmid pGEM-T-Easy (adapted from www.promega.com,  
Technical manual No. 042) 
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Restriction map of pUC 18\19 (adapted from www.fermentas.com/en/products/all/molecular-
cloning/vectors-phage/sd005-puc18-puc19). 
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